Enhanced protein compositions
By fusion of the cap domain at the C-terminal end of the polypeptide, the problem of weakening interactions and anti-polypeptide antibody responses in the interaction between the polypeptide and the molecule is solved, and the stability and pharmacokinetic characteristics of the polypeptide are improved, which enhances its treatment value of application in.
Patent Information
- Application Number
- CN202380030318.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-27
- Filing Date
- 2023-01-26
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to effectively solve the problem of weakening interactions or anti-polypeptide antibody responses in the interaction between polypeptides and molecules, which affects its application in treatment.
A polypeptide exposed to the C-terminal fusion of the target binding region and the cap domain is designed to reduce the interaction and self-aggregation of the polypeptide with the reference by fusing the His cap domain or other specific amino acid sequences at the C-terminal , and improve pharmacodynamics. Learning characteristics.
It effectively reduces the interaction and self-aggregation of the peptide with reference materials, improves the stability and pharmacokinetic properties of the peptide, reduces the response of drug-resistant antibodies, and enhances its application potential in treatment.
Smart Images

Figure CN118946580A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 303,921, filed on January 27, 2022, which is incorporated herein by reference in its entirety.
[0003] Sequence Listing
[0004] This application contains a computer-readable sequence listing submitted in XML file format together with this application, and the entire contents of the computer-readable sequence listing are incorporated herein by reference in their entirety. The sequence listing XML file submitted in this application is named "14620-547-228_SEQ_LISTING.xml", created on January 26, 2023, and has a size of 67,678 bytes. Technical Field
[0005] The invention described herein teaches, inter alia, isolated polypeptides, including diagnostic polypeptides, prognostic polypeptides, and therapeutic polypeptides, such as, for example, polypeptides capable of binding to themselves or other polypeptides or molecules, comprising a cap domain (e.g., a His cap domain, a (His) 6 (i.e., HHHHHH (SEQ ID NO: 26)), SLSLSPGK (SEQ ID NO: 36), AS or TVAPTESS (SEQ ID NO: 37)) fused to an exposed carboxyl terminus ("C-terminus"). The invention described herein also teaches nucleic acids and / or expression vectors encoding these polypeptides; cells containing these polypeptides, nucleic acids and / or expression vectors; and compositions containing these polypeptides. Methods of making these polypeptides and methods of using these polypeptides are also taught. Background Art
[0006] The interaction of polypeptides with other molecules (including other polypeptides) is well known. (See, e.g., Titeca, Kevin; Lemmens, Irma; Tavernier, Jan; Eyckerman, Sven (29 June 2018), "Discovering cellular protein-protein interactions: Technological strategies and opportunities," Mass Spectrometry Reviews. 38 (1): 79–111. doi: 10.1002 / mas.21574. ISSN 0277-7037. PMID 29957823; and Herce HD, Deng W, Helma J, Leonhardt H, Cardoso MC (2013), "Visualization and targeted disruption of protein interactions in living cells," Nature Communications. 4: 2660). Such interacting polypeptides can exist in vitro and in vivo. (See, e.g., Jones S, Thornton JM (January 1996), "Principles of protein-protein interactions," Proceedings of the National Academy of Sciences of the United States of America. 93(1): 13–20. Bibcode: 1996 PNAS ... 93 ... 13J. doi: 10.1073 / pnas.93.1.13.PMC 40170. PMID 8552589.) Examples of polypeptides that interact with other molecules are polypeptides that interact with proteins, including antigen binding proteins such as antibodies.(See, e.g., Curr Drug Metab. 2011 May; 12(4):313–328, “Characterization of Drug Interactions with Serum Proteins by Using High-Performance Affinity Chromatography,” David S. Hage, Jeane the Anguizola, Omar Barnaby, Abby Jackson, Michelle J. Yoo, Efthimia Papastavros, Erika Pfaunmiller, Matt Sobansky, and Zenghan Tong.) Proteins have been reported to bind to isolated polypeptides and, in some cases, elicit anti-polypeptide antibody responses that may affect their use, such as in therapy. (See, e.g., “Studies of drug interactions with glycated human serum albumin by high-performance affinity chromatography,” Ryan Matsuda, So-Hwang Kye, Jeane the Anguizola and David S. Hage, Reviews in Analytical Chemistry). Summary of the invention
[0007] Against this background, the inventors of the present invention have discovered methods and compositions for preventing or ameliorating the interaction of polypeptides with molecules.
[0008] In one aspect, the present invention provides a separated polypeptide comprising one or more target binding regions and an exposed C-terminus fused to a cap domain, wherein the separated polypeptide exhibits a reduced interaction with a reference relative to the separated polypeptide in the absence of a cap domain and the interaction with a reference. The cap domain is heterologous to the exposed C-terminus and includes one or more amino acid residues (e.g., histidine). In some embodiments, the cap domain is composed of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37) or His cap domain. In some embodiments, the biological substance includes serum. In specific embodiments, the biological substance is human serum. In some embodiments, the biological substance includes blood plasma. In specific embodiments, the biological substance is human blood plasma. In some embodiments, the biological substance includes serum and blood plasma (e.g., human serum and human blood plasma).
[0009] In one aspect, the present invention provides an isolated polypeptide comprising one or more target binding regions and an exposed C-terminus fused to a His cap domain, wherein the isolated polypeptide exhibits a reduced interaction with a reference relative to the interaction of the isolated polypeptide with the reference when the His cap domain is absent. In some embodiments, the reference is a molecule present in a biological substance. In some embodiments, the biological substance includes serum. In specific embodiments, the biological substance is human serum. In some embodiments, the biological substance includes plasma. In specific embodiments, the biological substance is human plasma. In some embodiments, the biological substance includes serum and plasma (e.g., human serum and human plasma).
[0010] In some embodiments, the reference comprises an anti-drug antibody. In some embodiments, the anti-drug antibody is pre-existing in the serum and / or plasma of the subject. In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope.
[0011] In some embodiments, one or more target binding regions comprise an antibody variable domain or an antigen binding fragment thereof. In some embodiments, one or more target binding regions comprise a light chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, one or more target binding regions comprise a heavy antibody variable domain or an antigen binding fragment thereof.
[0012] In some embodiments, the cap domain consists of the amino acid sequence of the His cap domain or SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the His cap domain consists of a single histidine residue. In some embodiments, the His cap domain consists of two histidine residues. In some embodiments, the His cap domain consists of three histidine residues. In some embodiments, the His cap domain consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the His cap domain consists of five histidine residues (SEQ ID NO: 28).
[0013] In some embodiments, the exposed C-terminus consists of the amino acid sequence of VTVSS (SEQ ID NO: 21), VEIK (SEQ ID NO: 22), VEIKR (SEQ ID NO: 23), or VEIKRT (SEQ ID NO: 24). In some embodiments, the exposed C-terminus consists of the amino acid sequence of TKVTVL (SEQ ID NO: 38), TKLTVL (SEQ ID NO: 39), TQLIIL (SEQ ID NO: 40), TELTVL (SEQ ID NO: 41), or TQLTVL (SEQ ID NO: 42). In some embodiments, the exposed C-terminus consists of the amino acid sequence of TKLTVL (SEQ ID NO: 39), TKVTVL (SEQ ID NO: 38), NGLVYAG (SEQ ID NO: 43), NGLLYAG (SEQ ID NO: 44), or TRLTVL (SEQ ID NO: 45). In some embodiments, the exposed C-terminus consists of the amino acid sequence provided in Table 1.
[0014] In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20).
[0015] In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5. In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n (SEQ ID NO:47), TKVTVL(His)n (SEQ ID NO:46), NGLVYAG(His)n (SEQ ID NO:51), NGLLYAG(His)n (SEQ ID NO:52), or TRLTVL(His)n (SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5.
[0016] In some embodiments, the interaction with a reference is determined by an immunoassay. In some embodiments, the interaction with a reference is assessed in vitro. In some embodiments, the interaction with a reference is assessed in vivo.
[0017] In another aspect, provided herein is an isolated polypeptide comprising one or more target binding regions and an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), wherein the isolated polypeptide exhibits reduced aggregation when incubated with a biological substance relative to the aggregation exhibited by the isolated polypeptide when incubated with a biological substance in the absence of the cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)).
[0018] In some embodiments, incubation with biological matter includes incubation at about 37°C for about 5 days to about 14 days. In some embodiments, incubation with biological matter includes incubation at about 40°C for about 7 days to about 14 days. In some embodiments, incubation with biological matter includes incubation at about 40°C for about 2 days to about 7 days. In some embodiments, incubation with biological matter includes incubation at about 40°C for about 2 days to about 5 days. In some embodiments, incubation with biological matter includes incubation at about 4°C for about 7 days to about 14 days. In some embodiments, incubation with biological matter includes incubation at about 25°C for about 7 days to about 14 days. In some embodiments, incubation with biological matter includes incubation at about 25°C for about 2 days to about 7 days. In some embodiments, incubation with biological matter includes incubation at about 25°C for about 2 days to about 5 days.
[0019] In some embodiments, the biological substance comprises anti-drug antibodies. In some embodiments, the biological substance comprises anti-drug antibodies pre-existing in the serum and / or plasma of a subject (e.g., a human subject). In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, one or more target binding regions comprise an antibody variable domain or an antigen binding fragment thereof. In some embodiments, one or more target binding regions comprise a light chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, one or more target binding regions comprise a heavy antibody variable domain or an antigen binding fragment thereof.
[0020] In some embodiments, the cap domain consists of the amino acid sequence of the His cap domain or SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the His cap domain consists of a single histidine residue. In some embodiments, the His cap domain consists of two histidine residues. In some embodiments, the His cap domain consists of three histidine residues. In some embodiments, the His cap domain consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the His cap domain consists of five histidine residues (SEQ ID NO: 28).
[0021] In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5. In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n (SEQ ID NO:47), TKVTVL(His)n (SEQ ID NO:46), NGLVYAG(His)n (SEQ ID NO:51), NGLLYAG(His)n (SEQ ID NO:52), or TRLTVL(His)n (SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5.
[0022] In some embodiments, interactions with biological substances are assessed by size exclusion chromatography.
[0023] In another aspect, provided herein is an isolated polypeptide comprising one or more target binding regions and an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), wherein the self-aggregation exhibited by the isolated polypeptide is reduced under the same conditions relative to the self-aggregation exhibited by the isolated polypeptide in the absence of the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)).
[0024] In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, one or more target binding regions comprise an antibody variable domain or an antigen binding fragment thereof. In some embodiments, one or more target binding regions comprise a light chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, one or more target binding regions comprise a heavy antibody variable domain or an antigen binding fragment thereof.
[0025] In some embodiments, the cap domain consists of the amino acid sequence of the His cap domain or SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the His cap domain consists of a single histidine residue. In some embodiments, the His cap domain consists of two histidine residues. In some embodiments, the His cap domain consists of three histidine residues. In some embodiments, the His cap domain consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the His cap domain consists of five histidine residues (SEQ ID NO: 28).
[0026] In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5. In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n (SEQ ID NO:47), TKVTVL(His)n (SEQ ID NO:46), NGLVYAG(His)n (SEQ ID NO:51), NGLLYAG(His)n (SEQ IDNO:52), or TRLTVL(His)n (SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5.
[0027] In some embodiments, self-aggregation is reduced in a high concentration liquid formulation (HCLF). In some embodiments, the HCLF concentration comprises about 50 mg / mL to about 150 mg / mL of the isolated polypeptide. In some embodiments, self-aggregation is reduced under heat stress. In some embodiments, heat stress comprises incubation at 40°C for about two weeks. In some embodiments, self-aggregation is assessed by size exclusion chromatography.
[0028] In another aspect, provided herein is an isolated protein comprising: (a) a first polypeptide comprising a target binding region and an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)); and (b) a second polypeptide comprising a target binding region, wherein the isolated protein exhibits a reduced interaction with a reference object relative to the interaction of the isolated protein with the reference object in the absence of the cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In some embodiments, the presence of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) reduces neutralization of the protein relative to neutralization of the same protein in the absence of the cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In some embodiments, the presence of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) improves the safety of the protein relative to the safety of the same protein in the absence of the cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In some embodiments, the presence of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) improves the pharmacokinetic properties of the protein relative to the pharmacokinetic properties of the same protein in the absence of the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In some embodiments, the presence of a cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) reduces the interaction between a protein and an anti-drug antibody relative to the interaction of the protein with a reference in the absence of the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)).
[0029] In some embodiments, the exposed C-terminus of the first polypeptide comprises an anti-drug antibody epitope. In some embodiments, the exposed C-terminus of the second polypeptide comprises an anti-drug antibody epitope. In some embodiments, the second polypeptide comprises an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)).
[0030] In some embodiments, the target binding regions of the first polypeptide and the second polypeptide are capable of binding to different targets. In some embodiments, the target binding region of the first polypeptide comprises an antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the second polypeptide comprises an antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the first polypeptide comprises a light chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the second polypeptide comprises a light chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the first polypeptide comprises a heavy chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the second polypeptide comprises a heavy chain antibody variable domain or an antigen binding fragment thereof.
[0031] In some embodiments, the cap domain of the first polypeptide consists of a His cap domain or an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In specific embodiments, the cap domain of the first polypeptide consists of a His cap domain. In some embodiments, the cap domain of the second polypeptide consists of a His cap domain or an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In specific embodiments, the cap domain of the second polypeptide consists of a His cap domain. In some embodiments, the His cap domain of the first polypeptide consists of a single histidine residue. In some embodiments, the His cap domain of the second polypeptide consists of a single histidine residue. In some embodiments, the His cap domain of the first polypeptide consists of two histidine residues. In some embodiments, the His cap domain of the second polypeptide consists of two histidine residues. In some embodiments, the His cap domain of the first polypeptide consists of three histidine residues. In some embodiments, the His cap domain of the second polypeptide consists of three histidine residues. In some embodiments, the His cap domain of the first polypeptide consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the His cap domain of the second polypeptide consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the His cap domain of the first polypeptide consists of five histidine residues (SEQ ID NO: 28). In some embodiments, the His cap domain of the second polypeptide consists of five histidine residues (SEQ ID NO: 28).
[0032] In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n (SEQ ID NO:47), TKVTVL(His)n (SEQ ID NO:46), NGLVYAG(His)n (SEQ ID NO:51), NGLLYAG(His)n (SEQ ID NO:52), or TRLTVL(His)n (SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5.
[0033] In some embodiments, the isolated protein further comprises a third polypeptide comprising a target binding region. In some embodiments, the third polypeptide comprises an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In some embodiments, the third polypeptide is capable of binding to a target different from the first polypeptide, the second polypeptide, or both. In some embodiments, the cap domain is a His cap domain.
[0034] In some embodiments, the exposed C-terminus of the third polypeptide comprises an anti-drug antibody epitope. In some embodiments, the target binding region of the third polypeptide comprises an antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the third polypeptide comprises a light chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the third polypeptide comprises a heavy chain antibody variable domain or an antigen binding fragment thereof.
[0035] In some embodiments, the His cap domain of the third polypeptide consists of a single histidine residue. In some embodiments, the His cap domain of the third polypeptide consists of two histidine residues. In some embodiments, the His cap domain of the third polypeptide consists of three histidine residues. In some embodiments, the His cap domain of the third polypeptide consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the His cap domain of the third polypeptide consists of five histidine residues (SEQ ID NO: 28).
[0036] In some embodiments, the exposed C-terminus of the third polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus of the third polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus of the third polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus of the third polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus of the third polypeptide fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.In some embodiments, the exposed C-terminus of the third polypeptide fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n(SEQ ID NO:47), TKVTVL(His)n(SEQ ID NO:46), NGLVYAG(His)n(SEQ ID NO:51), NGLLYAG(His)n(SEQ ID NO:52) or TRLTVL(His)n(SEQ ID NO:53), wherein n is 1, 2, 3, 4 or 5.
[0037] In some embodiments, the isolated protein is bispecific. In some embodiments, the isolated protein is multispecific. In some embodiments, the isolated protein is multispecific, such as, for example, trispecific. In some embodiments, the isolated protein is heterodimeric.
[0038] In another aspect, provided herein is an isolated nucleic acid sequence comprising a nucleotide sequence encoding a polypeptide provided herein or a protein provided herein.
[0039] In another aspect, provided herein is an isolated cell expressing a polypeptide provided herein or a protein provided herein.
[0040] In another aspect, provided herein is an expression vector comprising a nucleotide sequence encoding a polypeptide provided herein or a protein provided herein.
[0041] In another aspect, provided herein is an isolated cell comprising a nucleotide sequence encoding a polypeptide provided herein or a protein provided herein, or an expression vector comprising a nucleotide sequence encoding a polypeptide provided herein or a protein provided herein.
[0042] In another aspect, the present invention provides a method for producing a polypeptide provided herein or a protein provided herein, the method comprising culturing a cell provided herein. In some embodiments, the method further comprises isolating the polypeptide or protein.
[0043] In another aspect, provided herein is a bispecific antibody or multispecific antibody comprising one or more target binding regions and an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), wherein the antibody exhibits a reduced interaction with an anti-drug antibody relative to the interaction of the antibody with the anti-drug antibody in the absence of the cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In some embodiments, the anti-drug antibody is pre-existing in the serum and / or plasma of a subject (e.g., a human subject). In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, in an immunoassay, the antibody exhibits a reduced interaction with the anti-drug antibody relative to the interaction of the antibody with the anti-drug antibody in the absence of the His cap domain. In some embodiments, the one or more target binding regions comprise at least one antibody variable domain. In some embodiments, at least one antibody variable domain comprises a heavy chain variable domain. In some embodiments, at least one antibody variable domain comprises a light chain variable domain.
[0044] In some embodiments, the cap domain consists of the amino acid sequence of the His cap domain or SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the His cap domain consists of a single histidine residue. In some embodiments, the His cap domain consists of two histidine residues. In some embodiments, the His cap domain consists of three histidine residues. In some embodiments, the His cap domain consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the His cap domain consists of five histidine residues (SEQ ID NO: 28).
[0045] In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n (SEQ ID NO:47), TKVTVL(His)n (SEQ ID NO:46), NGLVYAG(His)n (SEQ ID NO:51), NGLLYAG(His)n (SEQ ID NO:52), or TRLTVL(His)n (SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5.
[0046] In some embodiments, the multispecific antibody comprises a trispecific antibody.
[0047] In another aspect, provided herein is a nucleic acid sequence comprising a nucleotide sequence encoding an antibody provided herein.
[0048] In another aspect, provided herein is an expression vector comprising a nucleic acid sequence comprising a nucleotide sequence encoding an antibody provided herein.
[0049] In another aspect, provided herein is an isolated cell comprising a nucleotide sequence encoding an antibody provided herein, or an expression vector comprising a nucleic acid sequence comprising a nucleotide sequence encoding an antibody provided herein.
[0050] In another aspect, provided herein is an isolated cell expressing an antibody provided herein.
[0051] In another aspect, the present invention provides a method for producing an antibody provided herein, the method comprising culturing a cell provided herein. In some embodiments, the method further comprises isolating the antibody.
[0052] In another aspect, provided herein is a method for reducing the interaction between an isolated polypeptide and a reference, wherein the isolated polypeptide comprises one or more target binding regions and an exposed C-terminus, the method comprising fusing a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) at the end of the exposed C-terminus. In some embodiments, the reference is a molecule present in a biological substance. In some embodiments, the biological substance comprises serum. In specific embodiments, the biological substance is human serum. In some embodiments, the biological substance comprises plasma. In specific embodiments, the biological substance is human plasma.
[0053] In some embodiments, the reference comprises an anti-drug antibody. In some embodiments, the reference comprises an anti-drug antibody pre-existing in the serum and / or plasma of a subject (e.g., a human subject). In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope.
[0054] In some embodiments, one or more target binding regions comprise an antibody variable domain or an antigen binding fragment thereof. In some embodiments, one or more target binding regions comprise a light chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, one or more target binding regions comprise a heavy antibody variable domain or an antigen binding fragment thereof.
[0055] In some embodiments, the cap domain consists of the amino acid sequence of the His cap domain or SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the His cap domain consists of a single histidine residue. In some embodiments, the His cap domain consists of two histidine residues. In some embodiments, the His cap domain consists of three histidine residues. In some embodiments, the His cap domain consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the His cap domain consists of five histidine residues (SEQ ID NO: 28).
[0056] In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n (SEQ ID NO:47), TKVTVL(His)n (SEQ ID NO:46), NGLVYAG(His)n (SEQ ID NO:51), NGLLYAG(His)n (SEQ ID NO:52), or TRLTVL(His)n (SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5.
[0057] In some embodiments, the interaction with a reference is determined by an immunoassay. In some embodiments, the interaction with a reference is assessed in vitro. In some embodiments, the interaction with a reference is assessed in vivo.
[0058] In another aspect, provided herein is a method for reducing aggregation of an isolated polypeptide in a biological substance, wherein the isolated polypeptide comprises one or more target binding regions, and an exposed C-terminus, the method comprising fusing a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) at the end of the exposed C-terminus. In some embodiments, the biological substance comprises serum and / or plasma. In some embodiments, the biological substance is human serum. In some embodiments, the biological substance is human plasma.
[0059] In some embodiments, incubation with biological matter includes incubation at about 37°C for about 5 days to about 14 days. In some embodiments, incubation with biological matter includes incubation at 37°C for about 2 days to about 7 days. In some embodiments, incubation with biological matter includes incubation at 37°C for about 2 days to about 5 days. In some embodiments, incubation with biological matter includes incubation at about 40°C for about 7 days to about 14 days. In some embodiments, incubation with biological matter includes incubation at 40°C for about 2 days to about 7 days. In some embodiments, incubation with biological matter includes incubation at 40°C for about 2 days to about 5 days. In some embodiments, incubation with biological matter includes incubation at about 4°C for about 7 days to about 14 days. In some embodiments, incubation with biological matter includes incubation at 4°C for about 2 days to about 7 days. In some embodiments, incubation with biological matter includes incubation at 4°C for about 2 days to about 5 days. In some embodiments, incubation with biological matter includes incubation at about 25°C for about 7 days to about 14 days. In some embodiments, incubating with the biological mass comprises incubating at 25°C for about 2 days to about 7 days. In some embodiments, incubating with the biological mass comprises incubating at 25°C for about 2 days to about 5 days.
[0060] In some embodiments, the biological substance comprises antidrug antibodies. In some embodiments, the antidrug antibodies are pre-existing in the serum and / or plasma of a subject (e.g., a human subject). In some embodiments, the exposed C-terminus comprises an antidrug antibody epitope. In some embodiments, one or more target binding regions comprise an antibody variable domain or an antigen binding fragment thereof. In some embodiments, one or more target binding regions comprise a light chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, one or more target binding regions comprise a heavy antibody variable domain or an antigen binding fragment thereof.
[0061] In some embodiments, the cap domain consists of the amino acid sequence of the His cap domain or SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the His cap domain consists of a single histidine residue. In some embodiments, the His cap domain consists of two histidine residues. In some embodiments, the His cap domain consists of three histidine residues. In some embodiments, the His cap domain consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the His cap domain consists of five histidine residues (SEQ ID NO: 28).
[0062] In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5. In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n (SEQ ID NO:47), TKVTVL(His)n (SEQ ID NO:46), NGLVYAG(His)n (SEQ ID NO:51), NGLLYAG(His)n (SEQ ID NO:52), or TRLTVL(His)n (SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5.
[0063] In some embodiments, interactions with biological substances are assessed by size exclusion chromatography.
[0064] On the other hand, provided herein is a method for reducing self-aggregation of an isolated polypeptide, wherein the isolated polypeptide comprises one or more target binding regions, and an exposed C-terminus, the method comprising fusing a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) at the end of the exposed C-terminus.
[0065] In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, one or more target binding regions comprise an antibody variable domain or an antigen binding fragment thereof. In some embodiments, one or more target binding regions comprise a light chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, one or more target binding regions comprise a heavy antibody variable domain or an antigen binding fragment thereof.
[0066] In some embodiments, the cap domain consists of the amino acid sequence of the His cap domain or SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the His cap domain consists of a single histidine residue. In some embodiments, the His cap domain consists of two histidine residues. In some embodiments, the His cap domain consists of three histidine residues. In some embodiments, the His cap domain consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the His cap domain consists of five histidine residues (SEQ ID NO: 28).
[0067] In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n (SEQ ID NO:47), TKVTVL(His)n (SEQ ID NO:46), NGLVYAG(His)n (SEQ ID NO:51), NGLLYAG(His)n (SEQ ID NO:52), or TRLTVL(His)n (SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5.
[0068] In some embodiments, self-aggregation is reduced in a high concentration liquid formulation (HCLF). In some embodiments, the HCLF concentration comprises about 50 mg / mL to about 150 mg / mL of the isolated polypeptide. In some embodiments, self-aggregation is reduced under heat stress. In some embodiments, heat stress comprises incubation at 40°C for about two weeks. In some embodiments, self-aggregation is assessed by size exclusion chromatography.
[0069] On the other hand, the present invention provides a method for reducing the interaction between an isolated protein and a reference, wherein the isolated protein comprises: (a) a first polypeptide comprising a target binding region and an exposed C-terminus; and (b) a second polypeptide comprising a target binding region, the method comprising fusing a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) at the end of the exposed C-terminus. In some embodiments, the exposed C-terminus of the first polypeptide comprises an anti-drug antibody epitope. In some embodiments, the exposed C-terminus of the second polypeptide comprises an anti-drug antibody epitope. In some embodiments, the second polypeptide comprises an exposed C-terminus and the method further comprises fusing a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus of the second polypeptide. In some embodiments, the target binding regions of the first polypeptide and the second polypeptide are capable of binding to different targets.
[0070] In some embodiments, the target binding region of the first polypeptide comprises an antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the second polypeptide comprises an antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the first polypeptide comprises a light chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the second polypeptide comprises a light chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the first polypeptide comprises a heavy chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the second polypeptide comprises a heavy chain antibody variable domain or an antigen binding fragment thereof.
[0071] In some embodiments, the cap domain of the first polypeptide consists of the amino acid sequence of His cap domain or SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the cap domain of the second polypeptide consists of the amino acid sequence of His cap domain or SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the His cap domain of the first polypeptide consists of a single histidine residue. In some embodiments, the His cap domain of the second polypeptide consists of a single histidine residue. In some embodiments, the His cap domain of the first polypeptide consists of two histidine residues. In some embodiments, the His cap domain of the second polypeptide consists of two histidine residues. In some embodiments, the His cap domain of the first polypeptide consists of three histidine residues. In some embodiments, the His cap domain of the second polypeptide consists of three histidine residues. In some embodiments, the His cap domain of the first polypeptide consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the His cap domain of the second polypeptide consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the first polypeptide consists of five histidine residues (SEQ ID NO: 28). In some embodiments, the His cap domain of the second polypeptide consists of five histidine residues (SEQ ID NO: 28).
[0072] In some embodiments, the exposed C-terminus of the first polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus of the first polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus of the first polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus of the first polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus of the first polypeptide fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.In some embodiments, the exposed C-terminus of the first polypeptide fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n (SEQ ID NO:47), TKVTVL(His)n (SEQ ID NO:46), NGLVYAG(His)n (SEQ ID NO:51), NGLLYAG(His)n (SEQ ID NO:52), or TRLTVL(His)n (SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5.
[0073] In some embodiments, the exposed C-terminus of the second polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus of the second polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus of the second polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus of the second polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus of the second polypeptide fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.In some embodiments, the exposed C-terminus of the second polypeptide fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n (SEQ ID NO:47), TKVTVL(His)n (SEQ ID NO:46), NGLVYAG(His)n (SEQ ID NO:51), NGLLYAG(His)n (SEQ ID NO:52), or TRLTVL(His)n (SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5.
[0074] In some embodiments, the isolated protein further comprises a third polypeptide comprising a target binding region. In some embodiments, the third polypeptide comprises an exposed C-terminus and the method further comprises fusing a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus of the third polypeptide. In some embodiments, the third polypeptide is capable of binding to a target different from the first polypeptide, the second polypeptide, or both. In some embodiments, the exposed C-terminus of the third polypeptide comprises an antidrug antibody epitope. In some embodiments, the target binding region of the third polypeptide comprises an antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the third polypeptide comprises a light chain antibody variable domain or an antigen binding fragment thereof. In some embodiments, the target binding region of the third polypeptide comprises a heavy chain antibody variable domain or an antigen binding fragment thereof.
[0075] In some embodiments, the cap domain of the third polypeptide consists of a His cap domain or an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the His cap domain of the third polypeptide consists of a single histidine residue. In some embodiments, the His cap domain of the third polypeptide consists of two histidine residues. In some embodiments, the His cap domain of the third polypeptide consists of three histidine residues. In some embodiments, the His cap domain of the third polypeptide consists of four histidine residues (SEQ ID NO: 27). In some embodiments, the His cap domain of the third polypeptide consists of five histidine residues (SEQ ID NO: 28).
[0076] In some embodiments, the exposed C-terminus of the third polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus of the third polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus of the third polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus of the third polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus of the third polypeptide fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.In some embodiments, the exposed C-terminus of the third polypeptide fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n(SEQ ID NO:47), TKVTVL(His)n(SEQ ID NO:46), NGLVYAG(His)n(SEQ ID NO:51), NGLLYAG(His)n(SEQ ID NO:52) or TRLTVL(His)n(SEQ ID NO:53), wherein n is 1, 2, 3, 4 or 5.
[0077] In some embodiments, the isolated protein is bispecific. In some embodiments, the isolated protein is multispecific. In some embodiments, the isolated protein is trispecific. In some embodiments, the isolated protein is heterodimeric.
[0078] On the other hand, a capping member (e.g., a histidine capping member) for reducing the interaction between an isolated polypeptide and a reference is provided herein, wherein the isolated polypeptide comprises one or more target binding regions and an exposed C-terminus. In some embodiments, the one or more target binding regions comprise an antibody variable domain or an antigen binding fragment thereof. In some embodiments, the reference is a molecule present in a biological substance. In some embodiments, the biological substance comprises serum and / or plasma. In some embodiments, the biological substance comprises serum (e.g., human serum). In some embodiments, the biological substance comprises plasma (e.g., human plasma). In some embodiments, the reference comprises an antidrug antibody. In some embodiments, the reference comprises an antidrug antibody pre-existing in the serum and / or plasma of a subject (e.g., a human subject). In some embodiments, the exposed C-terminus comprises an antidrug antibody epitope. In some embodiments, the exposed C-terminus consists of an amino acid sequence selected from the group consisting of VTVSS (SEQ ID NO: 21), VEIK (SEQ ID NO: 22), VEIKR (SEQ ID NO: 23), VEIKRT (SEQ ID NO: 24), TKVTVL (SEQ ID NO: 38), TKLTVL (SEQ ID NO: 39), TQLIIL (SEQ ID NO: 40), TELTVL (SEQ ID NO: 41), and TQLTVL (SEQ ID NO: 42). In some embodiments, the exposed C-terminus consists of an amino acid sequence provided in Table 1.
[0079] On the other hand, the present invention provides a capping component (e.g., a histidine capping component) for reducing the interaction between an isolated protein and a reference, wherein the isolated protein comprises: (a) a first polypeptide comprising a target binding region and an exposed C-terminus; and (b) a second polypeptide comprising a target binding region. In some embodiments, the second polypeptide comprises an exposed C-terminus. In some embodiments, the target binding regions of the first polypeptide and the second polypeptide are capable of binding to different targets. In some embodiments, the isolated protein further comprises a third polypeptide comprising a target binding region. In some embodiments, the third polypeptide comprises an exposed C-terminus. In some embodiments, the third polypeptide is capable of binding to a target different from the first polypeptide, the second polypeptide, or both. In some embodiments, the isolated protein is a heterodimer. In some embodiments, the isolated protein is bispecific or multispecific. In specific embodiments, the multispecific protein is trispecific. In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, the exposed C-terminus consists of an amino acid sequence selected from the group consisting of VTVSS (SEQ ID NO: 21), VEIK (SEQ ID NO: 22), VEIKR (SEQ ID NO: 23), and VEIKRT (SEQ ID NO: 24). In some embodiments, the reference comprises a molecule in a biological substance. In some embodiments, the biological substance comprises serum and / or plasma (e.g., human serum and / or human plasma). In some embodiments, the reference comprises an anti-drug antibody. In some embodiments, the anti-drug antibody pre-exists in the serum and / or plasma of a subject (e.g., a human subject).
[0080] On the other hand, a capping member (e.g., a histidine capping member) for reducing the interaction between a bispecific antibody or a multispecific antibody and a reference is provided herein, wherein the bispecific antibody or the multispecific antibody comprises one or more target binding regions and an exposed C-terminus. In some embodiments, the one or more target binding regions comprise at least one antibody variable domain. In some embodiments, at least one antibody variable domain comprises a heavy chain variable domain. In some embodiments, at least one antibody variable domain comprises a light chain variable domain. In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, the multispecific antibody comprises a trispecific antibody. In some embodiments, the reference comprises a molecule in a biological substance. In some embodiments, the biological substance comprises serum and / or plasma (e.g., human serum and / or human plasma). In some embodiments, the reference comprises an anti-drug antibody. In some embodiments, the anti-drug antibody is pre-existing in the serum and / or plasma of a subject (e.g., a human subject).
[0081] On the other hand, the present invention provides a separated polypeptide and a capping member (e.g., a histidine capping member) for reducing the interaction between the separated polypeptide and a reference, wherein the separated polypeptide comprises one or more target binding regions and an exposed C-terminus. In some embodiments, the one or more target binding regions comprise an antibody variable domain or an antigen binding fragment thereof. In some embodiments, the reference is a molecule present in a biological substance. In some embodiments, the biological substance comprises serum and / or plasma. In some embodiments, the biological substance comprises serum. In some embodiments, the biological substance comprises plasma. In some embodiments, the reference comprises an anti-drug antibody. In some embodiments, the anti-drug antibody is pre-existing in the serum and / or plasma of a subject (e.g., a human subject). In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, the exposed C-terminus consists of an amino acid sequence selected from the group consisting of VTVSS (SEQ ID NO: 21), VEIK (SEQ ID NO: 22), VEIKR (SEQ ID NO: 23), VEIKRT (SEQ ID NO: 24), TKVTVL (SEQ ID NO: 38), TKLTVL (SEQ ID NO: 39), TQLIIL (SEQ ID NO: 40), TELTVL (SEQ ID NO: 41), and TQLTVL (SEQ ID NO: 42). In some embodiments, the exposed C-terminus consists of an amino acid sequence provided in Table 1.
[0082] On the other hand, the present invention provides an isolated protein and a capping member (e.g., a histidine capping member) for reducing the interaction between the isolated protein and a reference, wherein the isolated protein comprises: (a) a first polypeptide comprising a target binding region and an exposed C-terminus; and (b) a second polypeptide comprising a target binding region. In some embodiments, the second polypeptide comprises an exposed C-terminus. In some embodiments, the target binding regions of the first polypeptide and the second polypeptide are capable of binding to different targets. In some embodiments, the isolated protein further comprises a third polypeptide comprising a target binding region. In some embodiments, the third polypeptide comprises an exposed C-terminus. In some embodiments, the third polypeptide is capable of binding to a target different from the first polypeptide, the second polypeptide, or both. In some embodiments, the isolated protein is a heterodimer. In some embodiments, the isolated protein is bispecific or multispecific. In some embodiments, the multispecific protein is trispecific. In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, the reference comprises a molecule in a biological substance. In some embodiments, the biological substance comprises serum and / or plasma. In some embodiments, the biological substance comprises serum and / or plasma (e.g., human serum and / or human plasma). In some embodiments, the reference comprises anti-drug antibodies. In some embodiments, the anti-drug antibodies are pre-existing in the serum and / or plasma of a subject (e.g., a human subject).
[0083] On the other hand, a bispecific antibody or a multispecific antibody and a capping member (e.g., a histidine capping member) for reducing the interaction between the separated protein and a reference are provided herein, wherein the bispecific antibody or the multispecific antibody comprises one or more target binding regions and an exposed C-terminus. In some embodiments, one or more target binding regions comprise at least one antibody variable domain. In some embodiments, at least one antibody variable domain comprises a heavy chain variable domain. In some embodiments, at least one antibody variable domain comprises a light chain variable domain. In some embodiments, the separated protein is a heterodimer. In some embodiments, the multispecific antibody comprises a trispecific antibody. In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, the reference comprises a molecule in a biological substance. In some embodiments, the biological substance comprises serum and / or plasma (e.g., human serum and / or human plasma). In some embodiments, the reference comprises an anti-drug antibody. In some embodiments, the anti-drug antibody is pre-existing in the serum and / or plasma of a subject (e.g., a human subject).
[0084] In one embodiment, the present invention provides an isolated protein for use in a diagnostic assay, the isolated protein comprising a target binding region and an exposed C-terminus fused to a cap domain, wherein the cap domain consists of a His cap domain, or an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In an embodiment, the protein is an antibody (e.g., a bispecific antibody or a multispecific antibody). In some embodiments, the antibody binds to: glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostein, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin. In some embodiments, the antibody binds to an antigen of a pathogen. In some embodiments, pathogens are viruses, bacteria, fungi or parasites. In some embodiments, proteins are used in diagnostic assays to detect the presence of molecules in biological substances. In some embodiments, molecules are antigens. In some embodiments, biological substances include serum and / or plasma (e.g., human serum and / or human plasma). In some embodiments, diagnostic assays are performed in vitro or in vivo. In some embodiments, the exposed C-terminus comprises an antidrug antibody epitope. In some embodiments, the exposed C-terminus is composed of an amino acid sequence selected from the group consisting of the following: VTVSS (SEQ ID NO: 21), VEIK (SEQ ID NO: 22), VEIKR (SEQ ID NO: 23), VEIKRT (SEQ ID NO: 24), TKVTVL (SEQ ID NO: 38), TKLTVL (SEQ ID NO: 39), TQLIIL (SEQ ID NO: 40), TELTVL (SEQ ID NO: 41) and TQLTVL (SEQ ID NO: 42).
[0085] In one embodiment, the present invention provides an isolated therapeutic protein for use in treatment, the isolated therapeutic protein comprising a target binding region and an exposed C-terminus fused to a cap domain, wherein the cap domain consists of an amino acid sequence of a His cap domain, or SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the protein is a cytokine or an antibody (e.g., a bispecific antibody or a multispecific antibody). In some embodiments, the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9 or IL-17. In some embodiments, the antibody binds to: glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostein, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin. In some embodiments, the antibody binds to an antigen of a pathogen. In some embodiments, the pathogen is a virus, a bacterium, a fungus or a parasite. In some embodiments, the exposed C-terminus comprises an antidrug antibody epitope. In some embodiments, the exposed C-terminus consists of an amino acid sequence selected from the group consisting of VTVSS (SEQ ID NO: 21), VEIK (SEQ ID NO: 22), VEIKR (SEQ ID NO: 23), VEIKRT (SEQ ID NO: 24), TKVTVL (SEQ ID NO: 38), TKLTVL (SEQ ID NO: 39), TQLIIL (SEQ ID NO: 40), TELTVL (SEQ ID NO: 41), and TQLTVL (SEQ ID NO: 42).
[0086] In some embodiments, provided herein is an isolated protein comprising a target binding region and an exposed C-terminus fused to a cap domain, wherein the exposed C-terminus consists of the amino acid sequence VTVSS (SEQ ID NO: 21), VEIK (SEQ ID NO: 22), VEIKR (SEQ ID NO: 23), VEIKRT (SEQ ID NO: 24), TKVTVL (SEQ ID NO: 38), TKLTVL (SEQ ID NO: 39), TQLIIL (SEQ ID NO: 40), TELTVL (SEQ ID NO: 41), or TQLTVL (SEQ ID NO: 42), and wherein the cap domain consists of the amino acid sequence of a His cap domain or SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the protein is an antibody (e.g., a bispecific antibody or a multispecific antibody). In some embodiments, the antibody binds to: glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostein, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin. In some embodiments, the antibody binds to an antigen of a pathogen. In some embodiments, the pathogen is a virus, bacteria, fungus, or parasite.
[0087] In one embodiment, provided herein is a therapeutic bispecific antibody or multispecific (e.g., trispecific) antibody for use in therapy, comprising two or more target binding regions and an exposed C-terminus fused to a cap domain, wherein the cap domain is a His cap domain, or an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the two or more target binding regions bind to two or more antigens. In some embodiments, at least one antigen is selected from the group consisting of: glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostein, PSMA, HER2 / neu, survival protein and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor and mesothelin. In some embodiments, the antibody binds to an antigen of a pathogen. In some embodiments, the pathogen is a virus, a bacterium, a fungus or a parasite. In some embodiments, the exposed C-terminus comprises an antidrug antibody epitope. In some embodiments, the exposed C-terminus consists of an amino acid sequence selected from the group consisting of VTVSS (SEQ ID NO: 21), VEIK (SEQ ID NO: 22), VEIKR (SEQ ID NO: 23), VEIKRT (SEQ ID NO: 24), TKVTVL (SEQ ID NO: 38), TKLTVL (SEQ ID NO: 39), TQLIIL (SEQ ID NO: 40), TELTVL (SEQ ID NO: 41) or TQLTVL (SEQ ID NO: 42).
[0088] On the other hand, provided herein is a pharmaceutical composition for use in treatment, comprising a protein (e.g., a bispecific antibody or a multispecific antibody) containing an exposed C-terminus and a cap domain and a pharmaceutically acceptable excipient. In one embodiment, provided herein is a pharmaceutical composition for use in treatment, comprising a protein as described herein, a bispecific antibody as described herein, or a multispecific (e.g., trispecific) antibody as described herein and a pharmaceutically acceptable excipient.
[0089] On the other hand, provided herein is a pharmaceutical composition for use in treatment, comprising a protein (e.g., a bispecific antibody or a multispecific antibody) containing an exposed C-terminus and a cap domain and a pharmaceutically acceptable excipient. In another embodiment, provided herein is a pharmaceutical composition for use in a diagnostic assay, comprising a protein as described herein, a bispecific antibody as described herein, or a multispecific (e.g., trispecific) antibody as described herein and a pharmaceutically acceptable excipient.
[0090] On the other hand, the present invention provides the use of a cap domain to reduce the interaction between an anti-drug antibody and a protein, wherein the protein comprises one or more target binding regions and an exposed C-terminus. In specific embodiments, the cap domain is a His cap domain or consists of an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, the cap domain is a His cap domain consisting of one, two, three, four or five histidines.
[0091] On the other hand, the present invention provides the use of a cap domain to reduce aggregation in a biological substance, wherein the protein comprises one or more target binding regions and an exposed C-terminus. In specific embodiments, the cap domain is a His cap domain or consists of an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the biological substance comprises serum and / or plasma (e.g., human serum and / or human plasma). In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, the cap domain is a His cap domain consisting of one, two, three, four or five histidines.
[0092] In another aspect, the present invention provides a use of a cap domain to reduce self-aggregation, wherein the protein comprises one or more target binding regions, and an exposed C-terminus. In specific embodiments, the cap domain is a His cap domain or consists of an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, the cap domain is a His cap domain consisting of one, two, three, four or five histidines.
[0093] In one embodiment, the present invention provides an isolated protein comprising a target binding region and an exposed C-terminus fused to a cap domain, wherein the cap domain consists of a His cap domain or an amino acid sequence of HHHHHH (SEQ ID NO: 26), SLSLSPGK (SEQ ID NO: 36) or AS, TVAPTESS (SEQ ID NO: 37). In some embodiments, the protein exhibits reduced interaction with anti-drug antibodies in biological substances. In some embodiments, the biological substance comprises serum and / or plasma (e.g., human serum and / or human plasma). In some embodiments, the exposed C-terminus comprises an anti-drug antibody epitope. In some embodiments, the exposed C-terminus consists of an amino acid sequence selected from the group consisting of VTVSS (SEQ ID NO: 21), VEIK (SEQ ID NO: 22), VEIKR (SEQ ID NO: 23), VEIKRT (SEQ ID NO: 24), TKVTVL (SEQ ID NO: 38), TKLTVL (SEQ ID NO: 39), TQLIIL (SEQ ID NO: 40), TELTVL (SEQ ID NO: 41), or TQLTVL (SEQ ID NO: 42). In some embodiments, for use in a therapeutic or diagnostic assay. BRIEF DESCRIPTION OF THE DRAWINGS
[0094] The foregoing summary, as well as the following detailed description of embodiments of the present application, will be better understood when read in conjunction with the accompanying drawings. It should be understood, however, that this patent application is not limited to the precise embodiments shown in the drawings.
[0095] Figure 1 An exemplary antibody structure (eg, an Fc-scFv antibody) comprising an Fc domain and two scFvs (eg, with the addition of one or more cap domains) suitable for use with the present invention is depicted.
[0096] Figure 2Exemplary antibody structures (eg, Fc-scFv x Fc antibody) comprising an Fc domain and a scFv heterodimerized with the Fc domain (eg, with the addition of one or more cap domains) suitable for use in the present invention are depicted.
[0097] Figure 3 Depicted are exemplary trispecific antibody structures (eg, HC-scFv x Fc-scFv trispecific antibodies) comprising a heavy chain and a scFv heterodimerized with an Fc domain and a scFv (eg, with the addition of one or more cap domains) suitable for use in the present invention.
[0098] Figure 4 An exemplary antibody structure (eg, HC x scFv-Fc-scFv) suitable for use in the present invention is depicted comprising a heavy chain heterodimerized with an Fc and two scFvs (eg, with the addition of one or more cap domains).
[0099] Figure 5 Depicted are exemplary bispecific antibody structures (eg, scFv-Fc-scFv bispecific antibodies) comprising an Fc domain and two scFvs heterodimerized with the Fc and two scFvs (eg, with the addition of one or more cap domains) suitable for use with the present invention.
[0100] Figure 6 Exemplary antibody structures comprising a variable heavy chain domain-Fc domain fusion (eg, Fc-VHH fusion) suitable for use with the present invention are depicted (eg, with the addition of one or more cap domains).
[0101] Figure 7 Depicted are exemplary multispecific antibody structures (e.g., scFv-Fc-VHH×HC-VHH) comprising an Fc domain, a scFv, and a variable heavy chain domain heterodimerized with heavy and variable heavy chain domains (e.g., with the addition of one or more cap domains) suitable for use in the present invention.
[0102] Figure 8 Depicted are exemplary multispecific antibodies (eg, trispecific antibodies) having a heavy chain heterodimerized with an Fc domain and two scFvs (eg, HC×scFv-Fc-scFv) (eg, with the addition of one or more cap domains) suitable for use in the present invention.
[0103] Fig. 9A and Fig. 9B The antigen binding region of the trispecific antibody is not C-terminal ( Fig. 9A ) or has ( Fig. 9B ) cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)).
[0104] Fig. 10A and Fig. 10B Depicted are exemplary trispecific antibodies having a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) at the C-terminus of the antigen binding region of the trispecific antibody. DETAILED DESCRIPTION
[0105] The present disclosure relates in part to proteins, such as therapeutic proteins (e.g., hormones, cytokines, enzymes, fusion proteins, or antibodies or other antigen binding proteins), modified with a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) at the exposed C-terminal protein. In a specific aspect, the present disclosure relates to an isolated protein comprising one or more target binding regions and an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In a specific embodiment, such a protein exhibits a reduced interaction with a reference relative to the interaction of the protein with the reference when the cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) is absent. In another specific embodiment, such proteins exhibit reduced aggregation when incubated with biological material relative to the aggregation exhibited by the protein when incubated with biological material in the absence of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In another specific embodiment, such proteins exhibit reduced self-aggregation relative to the self-aggregation exhibited by the protein in the absence of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)).
[0106] In a specific aspect, the present disclosure relates to proteins, such as therapeutic proteins (e.g., hormones, cytokines, enzymes, fusion proteins, or antibodies or other antigen binding proteins), modified with a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) that reduces or prevents an anti-drug antibody (ADA) response. In a specific aspect, the present disclosure relates to a protein having a (His) cap domain at the end of a non-naturally occurring C-terminal or C-terminal anti-drug antibody epitope. n(SEQ ID NO: 25), such as a therapeutic protein, wherein n is 1, 2, 3, 4 or 5, and (His) n The presence of the (SEQ ID NO: 25) sequence reduces or prevents the ADA response.
[0107] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. Otherwise, certain terms used herein have the meanings described in this specification. All patents, published patent applications, and publications cited herein are incorporated herein by reference as if fully described herein. For the purpose of interpreting this specification, the following terminology will be applied, and as long as appropriate, terms used in the singular will also include the plural, and vice versa. In the event that any description of the term described conflicts with any document incorporated herein by reference, the description of the term described below will prevail.
[0108] As used herein, abbreviations for the genetically encoded amino acids are conventional and are as follows:
[0109]
[0110]
[0111] It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0112] As used herein, the terms "about" and "approximately" mean within 20%, within 15%, within 10%, within 9%, within 8%, within 7%, within 6%, within 5%, within 4%, within 3%, within 2%, within 1% or less of a given value or range.
[0113] The term “between” as used in phrases such as “between A and B” or “between AB” refers to a range that includes both A and B.
[0114] As used herein, the term "anti-drug antibody" or "ADA" refers to an antibody that is capable of interacting with a protein such as a therapeutic protein (e.g., an antibody or another antigen binding protein). In a specific embodiment, the anti-drug antibody is pre-existing in the serum of a subject (e.g., a human subject). In another specific embodiment, the anti-drug antibody is pre-existing in the plasma of a subject (e.g., a human subject). In a specific embodiment, the anti-drug antibody binds to or cross-reacts with a polypeptide (e.g., an antigen binding protein, such as an antibody) or other protein comprising one or more target binding regions, and neutralizes the polypeptide or other protein. In certain embodiments, the anti-drug antibody alters the pharmacokinetic properties and / or safety characteristics of a polypeptide (e.g., an antigen binding protein, such as an antibody) or other protein comprising one or more target binding regions. In some embodiments, the anti-drug antibody inhibits the function of a polypeptide (e.g., an antigen binding protein, such as an antibody) or other protein (e.g., a therapeutic protein) comprising one or more target binding regions. In certain embodiments, the anti-drug antibody interferes with the binding of a polypeptide (e.g., an antigen binding protein, such as an antibody) comprising one or more target binding regions to one or more targets (e.g., one or more antigens).
[0115] As used herein, the term "target binding region" refers to a plurality of consecutive or non-consecutive amino acid residues in a polypeptide that can bind to a target (such as an antigen) in the presence of the target. In a specific embodiment, the target binding region comprises an antigen binding region.
[0116] As used herein, the term "exposed C-terminus" refers to the C-terminus of a polypeptide (e.g., such as a bispecific antibody, trispecific antibody, or other multispecific antibody), wherein a polypeptide having such a C-terminus, without a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) exhibits: (1) greater interaction with a reference than the same polypeptide with a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)); (2) greater aggregation with biological substances; (3) greater self-aggregation; or a combination thereof. In specific embodiments, the exposed C-terminus is only present in non-naturally occurring polypeptides (e.g., antibodies, such as bispecific antibodies, trispecific antibodies, or other multispecific antibodies). In specific embodiments, the exposed C-terminus is a sequence that is typically buried or otherwise not exposed in naturally occurring polypeptides (e.g., classical immunoglobulin constructs). In certain embodiments, the exposed C-terminus comprises a C-terminal anti-drug antibody epitope. In some embodiments, the exposed C-terminus is included in 4 to 6 C-terminal amino acid residues of a kappa light chain, a lambda light chain, or a variable heavy chain region of any species found, for example, at https: / / www.imgt.org / IMGTrepertoire / Proteins / index.php#B. In some embodiments, the exposed C-terminus is composed of 4 to 6 C-terminal amino acid residues of a kappa light chain, a lambda light chain, or a variable heavy chain region of any species found, for example, at https: / / www.imgt.org / IMGTrepertoire / Proteins / index.php#B. In some embodiments, the species is human, monkey, chicken, or cattle. In some embodiments, the exposed C-terminus is included in 4 to 6 C-terminal amino acid residues of a sequence found under IGKJ, IGLJ, or IGHJ of https: / / www.imgt.org / IMGTrepertoire / Proteins / index.php#B. In some embodiments, the exposed C-terminus comprises 4 to 6 C-terminal amino acid residues of a sequence found under IGKJ, IGLJ, or IGHJ at https: / / www.imgt.org / IMGTrepertoire / Proteins / index.php#B. In some embodiments, the exposed C-terminus consists of a C-terminal sequence of one of those sequences provided in Table 1. In some embodiments, the exposed C-terminus consists of 4 to 6 C-terminal amino acid residues of a sequence found under IGKJ, IGLJ, or IGHJ at https: / / www.imgt.org / IMGTrepertoire / Proteins / index.php#B.In some embodiments, the exposed C-terminus consists of a C-terminal sequence of one of those provided in Table 1.
[0117] Table 1
[0118]
[0119]
[0120] As used herein, the term "non-naturally occurring C-terminus" generally refers to a C-terminus that is not generally present as a C-terminus of a polypeptide or protein found in nature, such as a therapeutic protein or a diagnostic protein (e.g., an antigen binding protein). An example of a non-naturally occurring C-terminus of a protein is a C-terminus of a protein that is engineered or modified from its wild-type sequence (e.g., an antigen binding domain). In a specific embodiment, the non-naturally occurring C-terminus of a protein is a C-terminus of a protein that is not generally naturally exposed to interact with a reference (e.g., a biological substance or an ADA). In a specific embodiment, the non-naturally occurring C-terminus is an exposed C-terminus.
[0121] As used herein, the term "at the end" when used in the context of an exposed C-terminus refers to an exposed C-terminus or a non-naturally occurring C-terminus or the last amino acid residue of a C-terminal ADA epitope. For example, in some embodiments, an exposed C-terminus ending in the amino acid sequence VTVSS (SEQ ID NO: 21) and having a His cap domain fused to the end of the C-terminus can produce an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). Similarly, in some embodiments, an exposed C-terminus ending in the amino acid sequence VEIK (SEQ ID NO: 22) and having a His cap domain fused at the end of the C-terminus can produce an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In other embodiments, an exposed C-terminus ending in the amino acid sequence VEIKR (SEQ ID NO: 23) and having a His cap domain fused at the end of the C-terminus can produce an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In other embodiments, an exposed C-terminus terminating in the amino acid sequence VEIKRT (SEQ ID NO:24) and having a His cap domain fused to the C-terminus can produce an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20).In some embodiments, an exposed C-terminus terminating in the amino acid sequence TKVTVL (SEQ ID NO:38), TKLTVL (SEQ ID NO:39), TQLIIL (SEQ ID NO:40), TELTVL (SEQ ID NO:41), or TQLTVL (SEQ ID NO:42) and having a His cap domain fused at the end of the C-terminus can produce the amino acid sequence TKVTVL(His)n (SEQ ID NO:46), TKLTVL(His)n (SEQ ID NO:47), TQLIIL(His)n (SEQ ID NO:48), TELTVL(His)n (SEQ ID NO:49), or TQLTVL(His)n (SEQ ID NO:50), wherein n is 1, 2, 3, 4, or 5. In some embodiments, an exposed C-terminus ending in the amino acid sequence TKLTVL (SEQ ID NO:39), TKVTVL (SEQ ID NO:38), NGLVYAG (SEQ ID NO:43), NGLLYAG (SEQ ID NO:44), or TRLTVL (SEQ ID NO:45) and having a His cap domain fused at the end of the C-terminus can produce the amino acid sequence TKLTVL(His)n (SEQ ID NO:47), TKVTVL(His)n (SEQ ID NO:46), NGLVYAG(His)n (SEQ ID NO:51), NGLLYAG(His)n (SEQ ID NO:52), or TRLTVL(His)n (SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5.
[0122] As used herein, the term "cap domain" refers to amino acid residues that are not part of the exposed C-terminus of a polypeptide (e.g., an antibody, such as a bispecific antibody, a trispecific antibody, or other multispecific antibody). In other words, the cap domain is heterologous to the exposed C-terminus of the polypeptide (e.g., an antibody, such as a bispecific antibody, a trispecific antibody, or other multispecific antibody). In a specific embodiment, the cap domain consists of (His) 6 (i.e., HHHHHH (SEQ ID NO: 26), SLSLSPGK (SEQ ID NO: 36), AS, TVAPTESS (SEQ ID NO: 37), or a His cap domain. In some embodiments, the cap domain is not composed of (His) 6(i.e., HHHHHH (SEQ ID NO: 26)) or AS. In specific embodiments, the cap domain consists of a His cap domain. In specific embodiments, the cap domain does not interfere with one, two, three or more or all of the functions of the protein as assessed by techniques described herein or known to those of skill in the art. In specific embodiments, the cap domain does not interfere with the structure of the protein as assessed by techniques described herein or known to those of skill in the art.
[0123] As used herein, the term "capping component" refers to the presence or addition of an amino acid sequence consisting of (His)6 (i.e., HHHHHH (SEQ ID NO: 26)), SLSLSPGK (SEQ ID NO: 36), AS or TVAPTESS (SEQ ID NO: 37), or a His cap domain. In specific embodiments, the capping component refers to the presence or addition of an amino acid sequence consisting of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37), or a His cap domain. In some embodiments, the capping component does not refer to the presence or addition of an amino acid sequence consisting of the amino acid sequence of (His)6 (i.e., HHHHHH (SEQ ID NO: 26)) or AS.
[0124] As used herein, the term "His cap domain" refers to one or more histidine amino acid residues that are not part of the exposed C-terminus of a polypeptide (e.g., an antibody, such as a bispecific antibody, a trispecific antibody, or other multispecific antibody). In other words, the His cap domain is heterologous to the exposed C-terminus of a polypeptide (e.g., an antibody, such as a bispecific antibody, a trispecific antibody, or other multispecific antibody). In a specific embodiment, the His cap domain consists of (His) n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In another specific embodiment, the His cap domain consists of a single His. As used herein, the His cap domain does not contain (His) 6 (i.e., HHHHHH (SEQ ID NO: 26)). In specific embodiments, the His cap domain does not interfere with one, two, three or more, or all of the functions of the protein as assessed by techniques described herein or known to those of skill in the art. In specific embodiments, the His cap domain does not interfere with the structure of the protein as assessed by techniques described herein or known to those of skill in the art.
[0125] In view of this disclosure, those skilled in the art will understand that a "His capping component" consists of (His) n(SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the His capping component consists of a single His. Thus, the His capping component does not contain (His) 6 (ie, HHHHHH (SEQ ID NO:26)).
[0126] As used herein, the term "anti-drug antibody epitope" refers to a plurality of continuous or non-continuous amino acids recognized by ADA. In certain embodiments, the anti-drug antibody epitope is a new epitope or a new epitope-like structure in the C-terminus of a polypeptide (e.g., an antibody) or other protein comprising one or more target binding regions. In specific embodiments, the anti-drug antibody epitope is present only in non-naturally occurring antigen binding proteins (e.g., antibodies) or other proteins.
[0127] As used herein, the term "reference" refers to a substance or molecule that a polypeptide (e.g., an antibody, such as a bispecific antibody, a trispecific antibody, or other multispecific antibody) comprising an exposed C-terminus binds to. In specific embodiments, when bound to a polypeptide, the reference contacts the exposed C-terminus. For example, in certain embodiments, the reference comprises an antigen binding region, such as an anti-drug antibody, and the reference binds to an epitope of a polypeptide comprising an exposed C-terminus.
[0128] As used herein, the term "antibody" is used in the broadest sense and specifically encompasses, for example, monoclonal antibodies (including agonists, antagonists, neutralizing antibodies, full-length or intact monoclonal antibodies), antibody compositions with multi-epitope or mono-epitope specificity, polyclonal antibodies, monovalent antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific antibodies, trispecific antibodies, as long as they exhibit the desired biological activity), including but not limited to fusion molecules (e.g., IgG-scFv, scFv-Fc-scFv, VHH-Fc, Fc-VHH, Fc-scFv, HC-VHH, scFv-Fc-VHH, HC-scFv), single-chain antibodies and fragments thereof (e.g., domain antibodies), as described below. Antibodies can be human, humanized, chimeric and / or affinity matured, as well as antibodies from other species such as mice, rabbits, llamas, etc. The term "antibody" is intended to include polypeptide products of B cells within the class of immunoglobulin polypeptides, which are capable of binding to a specific molecular antigen and are composed of two pairs of identical polypeptide chains, wherein each pair has one heavy chain (about 50 kDa-70 kDa) and one light chain (about 25 kDa), each amino-terminal portion of each chain including a variable region of about 100 to about 130 or more amino acids, and each carboxyl-terminal portion of each chain including a constant region. See, e.g., Antibody Engineering (Borrebaeck, ed., 2nd ed., 1995); and Kuby, Immunology (3rd edition, 1997).
[0129] Antibodies also include, but are not limited to, synthetic antibodies, nanobodies, recombinantly produced antibodies, antibodies including those from camelid species (e.g., llamas or alpacas) or humanized variants thereof, intrabodies, anti-idiotypic (anti-Id) antibodies, and functional fragments (e.g., antigen-binding fragments) of any of the above, which refers to portions of antibody heavy or light chain polypeptides that retain some or all of the binding activity of the antibody from which the fragment is derived. Non-limiting examples of functional fragments (e.g., antigen-binding fragments) include single-chain Fv (scFv) (e.g., including monospecific, bispecific, etc.), Fab fragments, F(ab') fragments, F(ab) 2 Fragment, F(ab') 2 Fragments, disulfide bond-linked Fv (dsFv), Fd fragments, Fv fragments, diabodies, triabodies, tetrabodies and minibodies. Specifically, the antibodies provided herein include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, for example, antigen binding domains or molecules containing an antigen binding site that binds an antigen (e.g., one or more complementary determining regions (CDRs) of an antibody). Such antibody fragments can be found, for example, in Harlow and Lane, Antibodies:A Laboratory Manual (1989); Mol.Biology and Biotechnology: AComprehensive Desk Reference (Myers, ed., 1995); Huston et al., 1993, Cell Biophysics, Vol. 22: pp. 189-224; Plückthun and Skerra, 1989, Meth. Enzymol., Vol. 178: pp. 497-515; and Day, Advanced Immunochemistry (2nd edition, 1990). The antibodies provided herein can be any class (e.g., IgG, IgE, IgM, IgD, and IgA) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) of immunoglobulin molecules. The antibodies can be agonistic antibodies or antagonistic antibodies. The antibodies may be neither agonistic nor antagonistic.
[0130] In some embodiments, the antibodies may have modifications, wherein the modifications include cross-linkers, glycosylation, conjugated drugs, or thio-engineered thiol linkages.
[0131] As used herein, the term "antigen" has its ordinary meaning in the art. "Antigen" includes structures to which antigen binding proteins (e.g., antibodies) can bind. Antigens can be polypeptides, carbohydrates, nucleic acids, lipids, haptens, or other naturally occurring or synthetic compounds. In some embodiments, antigens are polypeptides. In certain embodiments, antigens are associated with cells, e.g., present on or in cells. In some embodiments, antigens are associated with cancer cells, e.g., present on or in cancer cells. In certain embodiments, antigens are associated with pathogens, such as viruses, bacteria, fungi, or parasites.
[0132] As used herein, the term "antigen binding protein" refers to a protein that binds to an antigen. Antibodies are examples of antigen binding proteins. Antigen binding proteins include, but are not limited to, single-chain antibodies, nanobodies, multidomain antibodies, scFv, Fab, and diabodies.
[0133] The term "binds" or "binding" refers to interactions between molecules, including, for example, the formation of a complex. The interactions can be, for example, non-covalent interactions, including hydrogen bonds, ionic bonds, hydrophobic interactions, and / or van der Waals interactions. A complex can also include a combination of two or more molecules held together by covalent or non-covalent bonds, interactions, or forces. The strength of the total non-covalent interactions between a single antigen binding site (such as an antigen binding site on an antibody) and a single epitope of a target molecule such as an antigen is the affinity of the antibody for that epitope. The dissociation rate (k) of a binding molecule (e.g., an antibody) from a monovalent antigen is the affinity of the antibody for that epitope. off ) and the association rate (k on ) ratio (k off / k on ) is the dissociation constant K D , which is inversely proportional to affinity. K D The lower the value, the higher the affinity of the antibody. D The value varies with different complexes of antibody and antigen and depends on the k on and k off Both. The dissociation constant K of the antibodies provided herein D Can use any method provided herein or any other method well-known to those skilled in the art to determine.The affinity at a binding site does not always reflect the true intensity of the interaction between antibody and antigen.When a composite antigen (such as a multivalent antigen) containing multiple repeated antigenic determinants contacts an antibody containing multiple binding sites, the interaction between antibody and antigen at one site will increase the probability of reacting at a second site.The intensity of this multiple interaction between multivalent antibody and antigen is called avidity.
[0134] Antigen binding proteins that bind or specifically bind to an antigen can be detected, for example, by immunoassays (e.g., ELISA, radioimmunoassay, and electrochemiluminescent immunoassay), Surface plasmon resonance (e.g., ) or other techniques known to those skilled in the art. In some embodiments, an antibody specifically binds to an antigen when it binds to the antigen with a higher affinity than to any cross-reactive antigen, as determined using experimental techniques such as radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA). Typically, a specific or selective reaction will be at least twice the background signal or noise, and can be more than 10 times the background. See, for example, Fundamental Immunology , pp. 332-336 (Paul ed., 2nd ed., 1989) for a discussion of binding specificity. In certain embodiments, the extent of binding of an antigen binding protein to a "non-target" protein is less than about 10% of the binding of the antigen binding protein to its specific target antigen, e.g., as determined by fluorescence activated cell sorting (FACS) analysis or RIA. An antigen binding protein that binds to an antigen includes an antigen binding protein that is capable of binding to the antigen with sufficient affinity such that the antigen binding protein can be used, e.g., as a therapeutic and / or diagnostic agent targeting the antigen. In certain embodiments, the antigen binding protein binds to the antigen with a dissociation constant (K) of less than or equal to 1 μM, 800 nM, 600 nM, 550 nM, 500 nM, 300 nM, 250 nM, 100 nM, 50 nM, 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, or 0.1 nM. D ). In certain embodiments, the antigen binding protein binds to an antigenic epitope that is conserved among antigens from different species.
[0135] In certain embodiments, the antigen binding protein may comprise a "chimeric" sequence in which a portion of the heavy and / or light chain is identical or homologous to a corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to a corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired biological activity (see U.S. Pat. No. 4,816,567; and Morrison et al., 1984, Proc. Natl. Acad. Sci. USA, Vol. 81: pp. 6851-6855). Chimeric sequences may include humanized sequences.
[0136] In certain embodiments, antigen-binding proteins may include a portion of a "humanized" form of a non-human (e.g., camel, murine, non-human primate) antibody, which includes a sequence from a human immunoglobulin (e.g., a receptor antibody), wherein the natural CDR residues are replaced by residues from non-human species such as camels, mice, rats, rabbits or non-human primates (e.g., donor antibodies) with the desired specificity, affinity and ability of the corresponding CDR. In some cases, one or more FR region residues of the human immunoglobulin sequence are replaced by corresponding non-human residues. In addition, humanized antibodies may include residues that are not present in the receptor antibody or the donor antibody. These modifications are made to further improve antibody performance. Humanized antibody heavy or light chains may include substantially all at least one or more variable regions, wherein all or substantially all CDRs correspond to those of non-human immunoglobulins, and all or substantially all FRs are those of human immunoglobulin sequences. In certain embodiments, humanized antibodies will include at least a portion of an immunoglobulin constant region (Fc), typically at least a portion of a constant region of a human immunoglobulin. For more details, see Jones et al., Nature, Vol. 321: pp. 522-525, 1986; Riechmann et al., Nature, Vol. 332: pp. 323-329, 1988; Presta, Curr. Op. Struct. Biol., Vol. 2: pp. 593-596, 1992; Carter et al., Proc. Natl. Acad. Sci. USA, Vol. 89: pp. 4285-4289, 1992; U.S. Pat. Nos. 6,800,738, 6,719,971, 6,639,055, 6,407,213 and 6,054,297.
[0137] In certain embodiments, the antigen binding protein may comprise a portion of a "fully human antibody" or "human antibody", wherein these terms are used interchangeably herein and refer to antibodies comprising human variable regions and, for example, human constant regions. The antigen binding protein may comprise an antibody sequence. In specific embodiments, these terms refer to antibodies comprising variable and constant regions of human origin. In certain embodiments, a "fully human" antibody may also encompass an antibody that binds to a polypeptide and is encoded by a nucleic acid sequence that is a naturally occurring somatic variant of a human germline immunoglobulin nucleic acid sequence. The term "fully human antibody" includes antibodies having variable and constant regions corresponding to human germline immunoglobulin sequences as described by Kabat et al. (see Kabat et al., 1991, Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242). A "human antibody" refers to an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human and / or that has been prepared using any technique for preparing human antibodies. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues. Human antibodies can be produced using various techniques known in the art, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., Vol. 227: p. 381, 1991; Marks et al., J. Mol. Biol., Vol. 222: p. 581, 1991) and yeast display libraries (Chao et al., Nature Protocols, Vol. 1: pp. 755-768, 2006). Methods that can also be used to prepare human monoclonal antibodies are described in Cole et al., Monoclonal Antibodies and Cancer Therapy , p. 77, 1985; Boerner et al., J. Immunol., Vol. 147 No. 1: pp. 86-95, 1991; and van Dijk and van de Winkel, Curr. Opin. Pharmacol., Vol. 5: pp. 368-374, 2001. Human antibodies can be prepared by administering an antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge but whose endogenous loci have been disabled, such as mice (see, e.g., Jakobovits, Curr. Opin. Biotechnol., Vol. 6 No. 5: pp. 561-566, 1995; Brüggemann and Taussing, Curr. Opin. Biotechnol., Vol. 8 No. 4: pp. 455-458, 1997; and about the XENOMOUSE TM Nos. 6,075,181 and 6,150,584 of the Human B Cell Hybridoma Technology). See also, e.g., Li et al., Proc. Natl. Acad. Sci. USA, Vol. 103: pp. 3557-3562, 2006 for human antibodies generated via human B cell hybridoma technology.
[0138] In certain embodiments, the antigen binding protein may include a portion of a "recombinant human antibody", wherein the phrase includes human antibodies prepared, expressed, produced or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant combinatorial human antibody library, antibodies isolated from transgenic and / or transchromosomal animals (e.g., mice or cattle) of human immunoglobulin genes (see, e.g., Taylor, LD et al., Nucl. Acids Res., Vol. 20: pp. 6287-6295, 1992) or antibodies prepared, expressed, produced or isolated by any other means involving splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies may have variable and constant regions derived from human germline immunoglobulin sequences (see Kabat, EA et al., 1991, Sequences of Proteins of Immunological Interest , Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242). However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when transgenic animals for human Ig sequences are used, in vivo somatic mutagenesis), and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
[0139] In certain embodiments, the antigen binding protein may comprise a portion of a "monoclonal antibody", wherein the term as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, e.g., the individual antibodies comprising the population are identical except for naturally occurring mutations that may be present in small amounts or well-known post-translational modifications such as amino acid phosphorylation or deamidation, methionine oxidation, or asparagine or glutamine deamidation, each monoclonal antibody will generally recognize a single epitope on the antigen. In specific embodiments, as used herein, a "monoclonal antibody" is an antibody produced by a single hybridoma or other cell. The term "monoclonal" is not limited to any particular method for preparing an antibody. For example, monoclonal antibodies useful in the present disclosure may be prepared by the hybridoma method first described by Kohler et al., Nature, Vol. 256: p. 495, 1975, or may be prepared using recombinant DNA methods in bacteria or eukaryotic or plant cells (see, e.g., U.S. Pat. No. 4,816,567). "Monoclonal antibodies" can also be isolated from phage antibody libraries using techniques described, for example, in Clackson et al., Nature, Vol. 352: 624-628, 1991 and Marks et al., J. Mol. Biol., Vol. 222: 581-597, 1991. Other methods for preparing clonal cell lines and monoclonal antibodies expressed thereby are well known in the art. See, for example, Short Protocols in Molecular Biology (Ausubel et al., eds., 5th ed., 2002).
[0140] A typical 4-chain antibody unit is a heterotetrameric glycoprotein consisting of two identical light (L) chains and two identical heavy (H) chains. In the case of IgG, the 4-chain unit is usually about 150,000 daltons. Each L chain is connected to the H chain by a covalent disulfide bond, and the two H chains are connected to each other by one or more disulfide bonds according to the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bonds. Each H chain has a variable domain (VH) at the N-terminus, followed by three constant domains (CH) of each of the α chain and the γ chain and four CH domains of the μ and ε isotypes. Each L chain has a variable domain (VL) at the N-terminus, followed by a constant domain (CL) at its other end. VL is aligned with VH, and CL is aligned with the first constant domain (CH1) of the heavy chain. It is believed that specific amino acid residues form an interface between the light chain and the heavy chain variable domains. The pairing of VH and VL together forms a single antigen binding site. For the structure and properties of antibodies of different classes, see, for example, Basic and Clinical Immunology , p. 71 (Stites et al., eds., 8th ed., 1994); and Immunobiology (Janeway et al. eds., 5th ed., 2001).
[0141] As used herein, the terms "Fab" and "Fab region" have their common meanings in the art. Generally, the term "Fab" or "Fab region" refers to the region of an antibody that binds to an antigen. Conventional IgG generally comprises two Fab regions, each Fab region residing on one of the two arms of the Y-shaped IgG structure. Each Fab region is generally composed of a variable region and a constant region of each of the heavy chain and the light chain. More specifically, the variable region and constant region of the heavy chain in the Fab region are VH and CH1 regions, and the variable region and constant region of the light chain in the Fab region are VL and CL regions. VH, CH1, VL and CL in the Fab region can be arranged in various ways to confer antigen binding ability according to the present disclosure. For example, VH and CH1 regions can be on one polypeptide, and VL and CL regions can be on separate polypeptides, similar to the Fab region of conventional IgG. Alternatively, VH, CH1, VL and CL regions can all be on the same polypeptide and oriented in different orders, as described in more detail in the following section.
[0142] As used herein, the terms "variable region" and "variable domain" have their common meanings in the art in the context of antibodies. Generally, the terms "variable region", "variable domain", "V region" or "V domain" refer to a part of the light chain or heavy chain of an antibody, which is usually located at the amino terminal of the light chain or heavy chain, and has a length of about 120 to 130 amino acids in the heavy chain and a length of about 100 to 110 amino acids in the light chain, and is used for the binding and specificity of each specific antibody to its specific antigen. The variable region of the heavy chain may be referred to as "VH". The variable region of the light chain may be referred to as "VL". The term "variable" refers to the fact that some fragments of the variable region are widely different in sequence between antibodies. The V region mediates antigen binding and defines the specificity of a specific antibody to its specific antigen. However, variability is not evenly distributed over the 110 amino acid spans of the variable region. In contrast, the V region consists of less variable (e.g., relatively invariant) stretches of about 15-30 amino acids called framework regions (FRs), separated by shorter regions of greater variability (e.g., extreme variability) called "hypervariable regions," each of which is about 9-12 amino acids long. The heavy and light chain variable regions each contain four FRs, largely adopting a β-sheet configuration, connected by three hypervariable regions, which form loops connecting and in some cases forming part of the β-pleated structure. The hypervariable regions in each chain are held together in close proximity by the FRs and with the hypervariable regions from the other chain, contributing to the formation of the antigen binding site of antibodies (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest(5th edition, 1991)). The constant region is not directly involved in the binding of the antibody to the antigen, but exhibits various effector functions, such as the participation of the antibody in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The variable region between different antibodies varies widely in sequence. In a specific embodiment, the variable region is a human variable region.
[0143] The term "variable region residue numbering according to Kabat" or "amino acid position numbering as in Kabat" and variations thereof refer to the numbering system for heavy chain variable regions or light chain variable regions used for antibody compilation in Kabat et al. (supra). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to the shortening or insertion of the FR or CDR of the variable domain. For example, the heavy chain variable domain may include a single amino acid insertion after residue 52 (residue 52a according to Kabat) and three inserted residues after residue 82 (e.g., residues 82a, 82b, and 82c, etc. according to Kabat). By comparing the homologous region of the antibody sequence with the "standard" Kabat numbering sequence, the Kabat residue numbering of a given antibody can be determined. When referring to the residues in the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain), the Kabat numbering system (e.g., Kabat et al., supra) is generally used. When referring to residues in the constant region of an immunoglobulin heavy chain, the "EU numbering system" or "EU index" (e.g., the EU index as reported by Kabat et al., supra) is generally used. The "EU index as in Kabat" refers to the residue numbering of the human IgG1 EU antibody. Other numbering systems have been described by, for example, AbM, Chothia, Contact, IMGT, and AHon.
[0144] As used herein, the term "heavy chain" has its ordinary meaning in the art in the context of antibodies. Generally, when used with reference to antibodies, the term "heavy chain" refers to a polypeptide chain of about 50-70 kDa, wherein the amino terminal portion includes a variable region of about 120 to 130 or more amino acids, and the carboxyl terminal portion includes a constant region. Based on the amino acid sequence of the heavy chain constant region, the constant region can be one of five different types (e.g., isotypes), referred to as α (α), δ (δ), ε (ε), γ (γ), and μ (μ). Different heavy chains are of different sizes: α, δ, and γ contain about 450 amino acids, while μ and ε contain about 550 amino acids. When combined with the light chain, these different types of heavy chains produce antibodies of five well-known categories (e.g., isotypes), i.e., IgA, IgD, IgE, IgG, and IgM, including four subclasses of IgG, i.e., IgG1, IgG2, IgG3, and IgG4. The sequences of heavy chains from various species are known in the art (see, e.g., i.e. internationalImMunoGeneTics information imgt.org).
[0145] As used herein, the term "light chain" has its ordinary meaning in the art in the context of antibodies. Generally, when used with reference to an antibody, the term "light chain" refers to a polypeptide chain of about 25 kDa, wherein the amino terminal portion includes a variable region of about 100 to about 110 or more amino acids, and the carboxyl terminal portion includes a constant region. The approximate length of the light chain is 211 to 217 amino acids. Based on the amino acid sequence of the constant domain, there are two different types, called kappa (κ) or lambda (λ). The sequences of light chains from various species are known in the art (see, e.g., i.e. international ImMunoGeneTicsinformation imgt.org). As used herein, the term "constant region" or "constant domain" in the context of antibodies has its ordinary meaning in the art. Typically, the term "constant region" or "constant domain" refers to the carboxyl terminal portion of the light chain and the heavy chain, which is not directly involved in the binding of the antibody to the antigen, but exhibits various effector functions, such as interactions with Fc receptors. Typically, the term refers to the portion of the immunoglobulin molecule that has a more conservative amino acid sequence relative to the rest of the immunoglobulin (the variable region containing the antigen binding site). The constant region may include the CH1, CH2 and CH3 regions of the heavy chain and the CL region of the light chain.
[0146] As used herein, the term "framework" or "FR" in the context of antibodies has its ordinary meaning in the art. Typically, the term "framework" or "FR" refers to those variable region residues that flank the CDRs. FR residues are present in, for example, chimeric, humanized, human domain antibodies, diabodies, linear antibodies, and bispecific antibodies. FR residues are those variable domain residues other than hypervariable region residues or CDR residues.
[0147] As used herein, the term "Fc region" of an antibody has its common meaning in the art. Typically, the term "Fc region" is used herein to define the C-terminal region of an immunoglobulin heavy chain, including, for example, a native sequence Fc region, a recombinant Fc region, and a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain may vary, the human IgG heavy chain Fc region is generally defined as extending from the amino acid residue at position Cys226 or from Pro230 to its carboxyl terminal. The C-terminal lysine in the Fc region (residue 447 is according to the EU numbering system) can be removed, for example, during the production or purification of the antibody or by recombinant engineering encoding nucleic acids of the heavy chain of the antibody. Therefore, the composition of a complete antibody can include an antibody population having all K447 residues removed, an antibody population having no K447 residue removed, and an antibody population having an antibody mixture containing and not containing the K447 residue. A "functional Fc region" has an "effector function" in a native sequence Fc region. Exemplary "effector functions" include C1q binding; CDC; Fc receptor binding; ADCC; phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors), etc. Such effector functions generally require an Fc region in combination with a binding region or binding domain (e.g., an antibody variable region or domain), and can be assessed using various assays known to those skilled in the art. A "variant Fc region" includes an amino acid sequence that differs from the amino acid sequence of a native sequence Fc region due to at least one amino acid modification (e.g., substitution, addition, or deletion). In certain embodiments, the variant Fc region has at least one amino acid substitution compared to the native sequence Fc region or the Fc region of a parent polypeptide, for example, about one to about ten amino acid substitutions in the native sequence Fc region or the Fc region of a parent polypeptide, or about one to about five amino acid substitutions. The variant Fc region herein may have at least about 80% homology with the Fc region of a native sequence Fc region and / or a parent polypeptide, or at least about A90% homology therewith, for example, at least about 95% homology therewith.
[0148] In certain embodiments, homology is determined by sequence similarity. Modern protein sequence databases are very comprehensive. Widely used similarity search programs such as BLAST (Altschul et al. 1997; Units 3.3 and 3.4), PSI-BLAST (Altschul et al., 1997), SSEARCH (Smith and Waterman, 1981; Pearson (1991), Unit 3.10), FASTA (Pearson and Lipman (1988) Unit 3.9) and HMMER3 (Johnson et al., 2010) programs produce accurate statistical estimates to ensure that protein sequences that share significant similarity also have similar structures.
[0149] The term "specificity" in the context of an antibody or other antibody binding protein refers to the selective recognition of a particular epitope of an antigen by an antigen binding protein. For example, natural antibodies are monospecific. As used herein, the term "multispecific" means that an antigen binding protein has two or more antigen binding sites, at least two of which bind to different antigens. As used herein, "bispecific" means that an antigen binding protein has two different antigen binding specificities. As used herein, the term "monospecific" antibody means an antigen binding protein having one or more binding sites, each binding site binding to the same antigen.
[0150] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein and refer to polymers of amino acids of any length. The polymer may be linear or branched, it may contain modified amino acids, and it may be interspersed with non-amino acids. The term also encompasses amino acid polymers that have been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification. The definition also includes, for example, polypeptides containing one or more amino acid analogs (including but not limited to non-natural amino acids), as well as other modifications known in the art. It should be understood that because the polypeptides of the present disclosure may be based on antibodies or other members of the immunoglobulin superfamily, in certain embodiments, a "polypeptide" may appear as a single chain or as two or more related chains.
[0151] "Polynucleotide", "nucleotide sequence" or "nucleic acid sequence" as used interchangeably herein refers to a polymer of nucleotides of any length and includes DNA and RNA. The nucleotides may be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and / or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase or by a synthetic reaction. A polynucleotide may contain modified nucleotides, such as methylated nucleotides and their analogs. As used herein, "oligonucleotide" refers to a short, usually single-stranded, synthetic polynucleotide, which is usually but not necessarily less than about 200 nucleotides in length. The terms "oligonucleotide" and "polynucleotide" are not mutually exclusive. The above description of polynucleotides is equally and fully applicable to oligonucleotides. Cells that produce the antigen-binding proteins of the present disclosure may include parent hybridoma cells, as well as bacterial and eukaryotic host cells into which nucleic acids encoding antibodies have been introduced. Unless otherwise indicated, the left end of any single-stranded polynucleotide sequence disclosed herein is the 5' end; the left direction of a double-stranded polynucleotide sequence is referred to as the 5' direction. The 5' to 3' direction of addition of the nascent RNA transcript is called the transcription direction; the sequence region on the DNA chain having the same sequence as the RNA transcript, which is from the 5' to 5' end of the RNA transcript, is called the "upstream sequence"; the sequence region on the DNA chain having the same sequence as the RNA transcript, which is from the 3' to 3' end of the RNA transcript, is called the "downstream sequence".
[0152] "Isolated" polynucleotides, nucleotide sequences, nucleic acid molecules or nucleic acid sequences are nucleic acid sequences that are basically separated from other RNA sequences, genomic DNA sequences and proteins or complexes such as ribosomes and polymerases that are naturally associated with native sequences, for example RNA sequences, DNA sequences or sequences containing nucleic acid mixtures. "Isolated" nucleic acid molecules are nucleic acid molecules that are separated from other nucleic acid molecules that are present in the natural source of the nucleic acid molecules. In addition, "isolated" polynucleotides, nucleotide sequences, nucleic acid molecules or nucleic acid sequences, such as cDNA molecules, can be substantially free of other cell materials or culture media when produced by recombinant technology, or substantially free of chemical precursors or other chemicals when chemically synthesized. In a specific embodiment, one or more polynucleotides, nucleotide sequences, nucleic acid molecules or nucleic acid sequences encoding antibodies or other antigen-binding proteins as described herein are separated or purified. The term encompasses polynucleotides, nucleotide sequences, nucleic acid molecules or nucleic acid sequences that have been removed from their naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs synthesized by heterologous systems. Substantially pure molecules can include isolated forms of the molecule. Specifically, an "isolated" polynucleotide, nucleotide sequence, nucleic acid molecule or nucleic acid sequence encoding an antibody or antigen binding protein described herein is a nucleic acid molecule that has been identified and separated from at least one contaminant nucleic acid molecule with which it is normally associated in the environment in which it is produced.
[0153] Unless otherwise indicated, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and encode the same amino acid sequence. The phrase "nucleotide sequence" encoding a protein or RNA may also include introns to the extent that the nucleotide sequence encoding the protein may contain introns in some versions.
[0154] The term "vector" refers to a material for carrying or containing a nucleic acid sequence so that the nucleic acid sequence is introduced into a host cell, the nucleic acid sequence including, for example, a nucleic acid encoding an antigen-binding protein (e.g., an antibody) as described herein. Applicable vectors include, for example, expression vectors, plasmids, phage vectors, viral vectors, episomes, and artificial chromosomes, which may include a selection sequence or marker operable for stable integration into a host cell chromosome. In addition, the vector may include one or more selective marker genes and appropriate expression control sequences. The selective marker genes that may be included, for example, provide resistance to antibiotics or toxins, supplement nutritional deficiencies, or provide key nutrients that are not in the culture medium. The expression control sequence may include constitutive and inducible promoters, transcription enhancers, transcription terminators, etc. that are well known in the art. When two or more nucleic acid molecules are co-expressed (e.g., antibody heavy chain and light chain or antibody VH and VL), both nucleic acid molecules may be inserted into, for example, a single expression vector or a separate expression vector. For single vector expression, the encoding nucleic acid may be operably connected to a common expression control sequence or to different expression control sequences, such as an inducible promoter and a constitutive promoter. The introduction of nucleic acid molecules into a host cell may be confirmed using methods well known in the art. Such methods include, for example, nucleic acid analysis, such as Northern blots or polymerase chain reaction (PCR) amplification of mRNA, immunoblotting for gene product expression, or other suitable analytical methods to test the expression of the introduced nucleic acid sequence or its corresponding gene product. It will be understood by those skilled in the art that the nucleic acid molecule is expressed in an amount sufficient to produce the desired product, and it is further understood that the expression level can be optimized using methods well known in the art to obtain sufficient expression.
[0155] As used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or state government or in a United States Pharmacopeia , European Pharmacopoeia or as listed in other recognized pharmacopoeias.
[0156] "Excipient" means a material, composition or vehicle, such as a liquid or solid filler, diluent, solvent or encapsulating material. Excipients include, for example, encapsulating materials or additives, such as absorption promoters, antioxidants, binders, buffers, carriers, coatings, colorants, diluents, disintegrants, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, spices, preservatives, propellants, release agents, sterilants, sweeteners, solubilizers, wetting agents and mixtures thereof. The term "excipient" may also refer to a diluent, adjuvant (e.g., Freund's adjuvant (complete or incomplete) or vehicle.
[0157] In some embodiments, the excipient is a pharmaceutically acceptable excipient. Examples of pharmaceutically acceptable excipients include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (e.g., less than about 10 amino acid residues) polypeptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as TWEEN TM , polyethylene glycol (PEG) and PLURONICS TM Other examples of pharmaceutically acceptable excipients are described in Remington and Gennaro, Remington's Pharmaceutical Sciences (18th edition, 1990).
[0158] In one embodiment, each component is "pharmaceutically acceptable" in the sense of being compatible with the other ingredients of the pharmaceutical formulation and suitable for use in contact with tissues or organs of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications commensurate with a reasonable benefit / risk ratio. See, e.g., Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al., eds.; The Pharmaceutical Press and the American Pharmaceutical Association, 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash, eds.; Gower Publishing Company, 2007; Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson, ed.; CRC Press LLC, Boca Raton, FL, 2009. In some embodiments, a pharmaceutically acceptable excipient is nontoxic to cells or mammals exposed thereto at the dosages and concentrations employed. In some embodiments, a pharmaceutically acceptable excipient is a pH buffered aqueous solution.
[0159] In some embodiments, excipient is a sterile liquid, such as water and oil, including those of petroleum, animal, plant or synthetic origin such as peanut oil, soybean oil, mineral oil, sesame oil, etc. When the composition (for example, pharmaceutical composition) is administered intravenously, water is an exemplary excipient. Saline solution and dextrose aqueous solution and glycerol solution can also be used as liquid excipients, especially for injection solution. Excipient can also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talcum, sodium chloride, skim milk powder, glycerol, propylene, glycol, water, ethanol, etc. If necessary, the composition can also contain a small amount of wetting agent or emulsifier or pH buffer. The composition can be in the form of solution, suspension, emulsion, tablet, pill, capsule, powder, sustained release preparation, etc. Oral composition, including preparation, can include standard excipients, such as pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, etc.
[0160] For example, a composition including a pharmaceutical compound may contain an antigen binding protein (eg, an antibody), eg, in isolated or purified form, together with a suitable amount of an excipient.
[0161] As used herein, the term "effective amount" or "therapeutically effective amount" refers to the amount of a polypeptide (e.g., antigen binding protein such as an antibody), agent (e.g., therapeutic protein or other agent), or pharmaceutical composition described herein sufficient to produce a desired result.
[0162] The terms "subject" and "patient" can be used interchangeably to refer to an animal. As used herein, in certain embodiments, the subject is a mammal, such as a non-primate or primate (e.g., a human). In a specific embodiment, the subject is a human. In one embodiment, the subject is a mammal, such as a human, diagnosed with a disease or disorder. In another embodiment, the subject is a mammal, such as a human, at risk of developing a disease or disorder. In certain embodiments, the subject is a non-human animal, such as a pet or farm animal (e.g., a dog, a cat, a cow, a pig, a horse, a donkey, etc.).
[0163] "Administering" refers to the act of injecting or otherwise physically delivering a substance present outside the body into a patient's body, such as by mucosal, intradermal, intravenous, intramuscular delivery, and / or any other physical delivery method described herein or known in the art.
[0164] Unless otherwise indicated, the practice of the embodiments provided herein will employ conventional techniques of molecular biology, microbiology, and immunology, which are within the skill of those skilled in the art. Such techniques are fully explained in the literature. Examples of texts that are particularly suitable for consultation include the following: Sambrook et al., Molecular Cloning: A Laboratory Manual, Third Ed., Cold Spring Harbor Laboratory, New York (2001); Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD (1999); Glover, ed., DNA Cloning, Volumes I and II (1985); Freshney, ed., Animal Cell Culture: Immobilized Cells and Enzymes (IRL Press, 1986); Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); Scopes, Protein Purification: Principles and Practice (Springer Verlag, NY, 2ded. 1987); Therapeutic Monoclonal Antibodies: From Bench to Clinic (edited by An, 2009); Monoclonal Antibodies: Methods and Protocols (Albitar, ed., 2010); and Antibody Engineering, Volumes 1 and 2 (Kontermann and Dübel, eds., 2nd edition, 2010).
[0165] In order to help the reader of the present application, the description has been divided into each paragraph or chapter, or relates to each embodiment of the present application. These divisions should not be considered as the main content of a paragraph or chapter or embodiment being separated from the main content of another paragraph or chapter or embodiment. On the contrary, it will be appreciated by those skilled in the art that this description has a wide range of applications, and encompasses all combinations of conceivable chapters, paragraphs and sentences. The discussion of any embodiment is intended to be exemplary only, and is not intended to indicate that the scope of the present disclosure (including claims) is limited to these examples. The application contemplates the use of any applicable component in any combination, regardless of whether a specific combination is explicitly described.
[0166] 7.1. protein
[0167] Provided herein are proteins (e.g., antibodies or other antigen binding proteins) comprising an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In specific embodiments, these proteins are therapeutic proteins. In some embodiments, the proteins are antigen binding proteins. In some embodiments, the antigen binding protein is any antigen binding protein, such as an antibody or immunoglobulin superfamily domain of interest, wherein an exposed C-terminus is present, for example, at the C-terminus of the protein, such as a VHH or scFv / spFv. In some embodiments, the antibody has Figure 1-9A The format shown in any of the .
[0168] The cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) fused to the exposed C-terminus of the polypeptide can be achieved by any method known in the art. In some embodiments, the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) is directly connected to the exposed C-terminus of the polypeptide. In some embodiments, the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) is conjugated to the exposed C-terminus of the polypeptide.
[0169] In a specific aspect, provided herein are proteins comprising a cap domain, such as described in Example 8.1 and / or Example 8.2 below. In a specific embodiment, the capped proteins provided herein have one or more properties of the capped trispecific antibodies described in Example 8.1 and / or Example 8.2 below. In a specific embodiment, the protein is a capped trispecific antibody described in Example 8.1 and / or Example 8.2 below.
[0170] In one aspect, provided herein is a polypeptide comprising one or more target binding regions (e.g., two, three or more target binding regions) and an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In some embodiments, the one or more target binding regions comprise an antibody variable domain (e.g., a heavy chain variable domain or a light chain variable domain) or an antigen binding fragment thereof. In some embodiments, the cap domain consists of the amino acid sequence of the His cap domain or SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In specific embodiments, the His cap domain consists of (His) n(SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n(SEQ ID NO:47), TKVTVL(His)n(SEQ ID NO:46), NGLVYAG(His)n(SEQ ID NO:51), NGLLYAG(His)n(SEQ ID NO:52), or TRLTVL(His)n(SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5. In a specific embodiment, the polypeptide is isolated.
[0171] On the other hand, the present invention provides a protein comprising (a) a first polypeptide comprising a target binding region and an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)); and (b) a second polypeptide comprising a target binding region. In some embodiments, the second polypeptide comprises an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In some embodiments, the target binding regions of the first polypeptide and the second polypeptide are capable of binding to different targets. In certain embodiments, the protein further comprises a third polypeptide comprising a target binding region. In some embodiments, the third polypeptide comprises an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In some embodiments, the third polypeptide is capable of binding to a target different from the first polypeptide, the second polypeptide, or both. In some embodiments, the target binding region comprises an antibody variable domain (e.g., a heavy chain variable domain or a light chain variable domain) or an antigen binding fragment thereof. In some embodiments, the cap domain consists of a His cap domain or an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37). In specific embodiments, the His cap domain consists of (His) n(SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9), and VEIKHHHHH (SEQ ID NO: 10). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14), and VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20). In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKVTVL(His)n(SEQ ID NO:46), TKLTVL(His)n(SEQ ID NO:47), TQLIIL(His)n(SEQ ID NO:48), TELTVL(His)n(SEQ ID NO:49) or TQLTVL(His)n(SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.In some embodiments, the exposed C-terminus fused to the His cap domain consists of the amino acid sequence of TKLTVL(His)n(SEQ ID NO:47), TKVTVL(His)n(SEQ ID NO:46), NGLVYAG(His)n(SEQ ID NO:51), NGLLYAG(His)n(SEQ ID NO:52), or TRLTVL(His)n(SEQ ID NO:53), wherein n is 1, 2, 3, 4, or 5. In some embodiments, the protein is trispecific. In some embodiments, the isolated protein is multispecific. In a specific embodiment, the protein is isolated.
[0172] In another aspect, the present invention provides a protein comprising an antigen binding region of an antibody, wherein the antigen binding region comprises an exposed C-terminus and a (His) at the end of the exposed C-terminus of the antibody binding region. n (SEQ ID NO: 25) sequence, wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the present invention provides a protein (e.g., an antigen binding protein) comprising an antibody variable domain, wherein the antibody variable domain comprises an exposed C-terminus and a (His) at the end of the exposed C-terminus of the antibody variable domain. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the present invention provides a protein comprising an antibody fragment, wherein the antibody fragment comprises an exposed C-terminus and a (His) at the end of the exposed C-terminus of the antibody fragment. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In some embodiments, (His) n The n of the sequence is 1. In certain embodiments, (His) n The n of the sequence is 2. In some embodiments, (His) n The n of the sequence is 3. In certain embodiments, (His) n The n of the sequence is 4 (SEQ ID NO: 27). In some embodiments, (His) nThe n of the sequence is 5 (SEQ ID NO:28). In certain embodiments, the antibody variable domain is a heavy chain variable domain. In specific embodiments, the heavy chain variable domain is not camelized. In specific embodiments, the exposed C-terminus consists of the amino acid sequence VTVSS (SEQ ID NO:21), LTVSS (SEQ ID NO:29) or VTVSA (SEQ ID NO:30). In certain embodiments, the antibody variable domain is a light chain variable domain. In specific embodiments, the exposed C-terminus consists of the amino acid sequence VEIK (SEQ ID NO:22), VEIKR (SEQ ID NO:23) or VEIKRT (SEQ ID NO:24). In specific embodiments, the protein is isolated.
[0173] In some embodiments, provided herein is a bispecific antibody comprising an antibody variable domain, wherein the antibody variable domain comprises an exposed C-terminus and a (His) at the end of the exposed C-terminus of the antibody variable domain. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In certain embodiments, provided herein is a multispecific antibody comprising an antibody variable domain, wherein the antibody variable domain comprises an exposed C-terminus and a (His) at the end of the exposed C-terminus of the antibody variable domain. n (SEQ ID NO:25) sequence, wherein n is 1, 2, 3, 4 or 5. In specific embodiments, the bispecific antibody or multispecific antibody is isolated. In certain embodiments, the antibody variable domain is a light chain variable domain. In other embodiments, the antibody variable domain is a heavy chain variable domain. In specific embodiments, the heavy chain variable domain is not camelized.
[0174] Heavy chain immunoglobulin variable (V H The C-terminal amino acid sequence of the ) domain generally has the sequence VTVSS (SEQ ID NO: 21) in humans and the sequence VTVSS (SEQ ID NO: 21), LTVSS (SEQ ID NO: 29) or VTVSA (SEQ ID NO: 30) in mice. L The C-terminal amino acid sequence of the ) domain generally has the sequence VEIK (SEQ ID NO: 22), VEIKR (SEQ ID NO: 23) or VEIKRT (SEQ ID NO: 24) in humans. In a classical immunoglobulin construct, V H The C-terminal amino acid of the domain is bound by the first heavy chain constant (CH 1) domain is buried and not exposed, and the C-terminal amino acid of the VL domain is replaced by the light chain constant (C L ) domain is buried and not exposed. However, antibody fragments can be engineered so that V H Domain or V L The C-termini of either domain or both are no longer unexposed. This effectively results in V H Domain or V L A portion of the domain is exposed that would not otherwise occur naturally. H Domain and / or V L Domain-specific antibody fragments can trigger an ADA response.
[0175] Thus, in one aspect, the present invention provides a protein (e.g., an antigen binding protein) comprising an antibody heavy chain variable domain, wherein the antibody heavy chain variable domain comprises a C-terminal amino acid sequence, wherein the last six to ten amino acid residues of the C-terminal amino acid sequence consist of the amino acid sequence VTVSS(H) n (SEQ ID NO:31), wherein n is 1, 2, 3, 4 or 5. In some embodiments, the C-terminal amino acid sequence consists of VTVSSH (SEQ ID NO:1). In some embodiments, the C-terminal amino acid sequence consists of VTVSSHH (SEQ ID NO:2). In some embodiments, the C-terminal amino acid sequence consists of VTVSSHHH (SEQ ID NO:3). In some embodiments, the C-terminal amino acid sequence consists of VTVSSHHHH (SEQ ID NO:4). In some embodiments, the C-terminal amino acid sequence consists of VTVSSHHHHH (SEQ ID NO:5). In specific embodiments, the protein is isolated.
[0176] In some embodiments, provided herein is a bispecific antibody comprising an antibody heavy chain variable domain, wherein the antibody heavy chain variable domain comprises a C-terminal amino acid sequence, wherein the last six to ten amino acid residues of the C-terminal amino acid sequence consist of the amino acid sequence VTVSS(H) n(SEQ ID NO:31), wherein n is 1, 2, 3, 4 or 5. In some embodiments, the C-terminal amino acid sequence consists of VTVSSH (SEQ ID NO:1). In some embodiments, the C-terminal amino acid sequence consists of VTVSSHH (SEQ ID NO:2). In some embodiments, the C-terminal amino acid sequence consists of VTVSSHHH (SEQ ID NO:3). In some embodiments, the C-terminal amino acid sequence consists of VTVSSHHHH (SEQ ID NO:4). In some embodiments, the C-terminal amino acid sequence consists of VTVSSHHHHH (SEQ ID NO:5). In specific embodiments, the bispecific antibody is isolated.
[0177] In certain embodiments, the present invention provides a multispecific antibody comprising an antibody heavy chain variable domain, wherein the antibody heavy chain variable domain comprises a C-terminal amino acid sequence, wherein the last six to ten amino acid residues of the C-terminal amino acid sequence consist of the amino acid sequence VTVSS(H) n (SEQ ID NO:31), wherein n is 1, 2, 3, 4 or 5. In some embodiments, the C-terminal amino acid sequence consists of VTVSSH (SEQ ID NO:1). In some embodiments, the C-terminal amino acid sequence consists of VTVSSHH (SEQ ID NO:2). In some embodiments, the C-terminal amino acid sequence consists of VTVSSHHH (SEQ ID NO:3). In some embodiments, the C-terminal amino acid sequence consists of VTVSSHHHH (SEQ ID NO:4). In some embodiments, the C-terminal amino acid sequence consists of VTVSSHHHHH (SEQ ID NO:5). In specific embodiments, the multispecific antibody is isolated. In certain embodiments, the multispecific antibody is trispecific.
[0178] In another aspect, the present invention provides a protein (e.g., an antigen binding protein) comprising an antibody light chain variable domain, wherein the antibody light chain variable domain comprises a C-terminal amino acid sequence, wherein the last five to eleven amino acid residues of the C-terminal amino acid sequence are composed of the amino acid sequence VEIK (H) n (SEQ ID NO:32), VEIKR(H) n (SEQ ID NO: 33) or VEIKRT (H) n(SEQ ID NO:34), and wherein n is 1, 2, 3, 4, or 5. In some embodiments, the C-terminal amino acid sequence consists of VEIKH (SEQ ID NO:6). In some embodiments, the C-terminal amino acid sequence consists of VEIKHH (SEQ ID NO:7). In some embodiments, the C-terminal amino acid sequence consists of VEIKHHH (SEQ ID NO:8). In some embodiments, the C-terminal amino acid sequence consists of VEIKHHHH (SEQ ID NO:9). In some embodiments, the C-terminal amino acid sequence consists of VEIKHHHHH (SEQ ID NO:10). In some embodiments, the C-terminal amino acid sequence consists of VEIKRH (SEQ ID NO:11). In some embodiments, the C-terminal amino acid sequence consists of VEIKRHH (SEQ ID NO:12). In some embodiments, the C-terminal amino acid sequence consists of VEIKRHHH (SEQ ID NO:13). In some embodiments, the C-terminal amino acid sequence consists of VEIKRHHHH (SEQ ID NO:14). In some embodiments, the C-terminal amino acid sequence consists of VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTH (SEQ ID NO: 16). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTHH (SEQ ID NO: 17). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTHHH (SEQ ID NO: 18). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTHHHH (SEQ ID NO: 19). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTHHHHH (SEQ ID NO: 20). In specific embodiments, the protein is isolated.
[0179] In certain embodiments, provided herein is a bispecific antibody comprising an antibody light chain variable domain, wherein the antibody light chain variable domain comprises a C-terminal amino acid sequence, wherein the last five to eleven amino acid residues of the C-terminal amino acid sequence are composed of the amino acid sequence VEIK(H) n (SEQ ID NO:32), VEIKR(H) n (SEQ ID NO: 33) or VEIKRT (H) n(SEQ ID NO:34), and wherein n is 1, 2, 3, 4, or 5. In some embodiments, the C-terminal amino acid sequence consists of VEIKH (SEQ ID NO:6). In some embodiments, the C-terminal amino acid sequence consists of VEIKHH (SEQ ID NO:7). In some embodiments, the C-terminal amino acid sequence consists of VEIKHHH (SEQ ID NO:8). In some embodiments, the C-terminal amino acid sequence consists of VEIKHHHH (SEQ ID NO:9). In some embodiments, the C-terminal amino acid sequence consists of VEIKHHHHH (SEQ ID NO:10). In some embodiments, the C-terminal amino acid sequence consists of VEIKRH (SEQ ID NO:11). In some embodiments, the C-terminal amino acid sequence consists of VEIKRHH (SEQ ID NO:12). In some embodiments, the C-terminal amino acid sequence consists of VEIKRHHH (SEQ ID NO:13). In some embodiments, the C-terminal amino acid sequence consists of VEIKRHHHH (SEQ ID NO:14). In some embodiments, the C-terminal amino acid sequence consists of VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTH (SEQ ID NO: 16). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTHH (SEQ ID NO: 17). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTHHH (SEQ ID NO: 18). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTHHHH (SEQ ID NO: 19). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTHHHHH (SEQ ID NO: 20). In specific embodiments, the bispecific antibodies are isolated.
[0180] In some embodiments, provided herein is a multispecific antibody (e.g., a trispecific antibody) comprising an antibody light chain variable domain, wherein the antibody light chain variable domain comprises a C-terminal amino acid sequence, wherein the last five to eleven amino acid residues of the C-terminal amino acid sequence consist of the amino acid sequence VEIK(H) n (SEQ ID NO:32), VEIKR(H) n (SEQ ID NO:33) or VEIKRT(H) n(SEQ ID NO:34), and wherein n is 1, 2, 3, 4, or 5. In some embodiments, the C-terminal amino acid sequence consists of VEIKH (SEQ ID NO:6). In some embodiments, the C-terminal amino acid sequence consists of VEIKHH (SEQ ID NO:7). In some embodiments, the C-terminal amino acid sequence consists of VEIKHHH (SEQ ID NO:8). In some embodiments, the C-terminal amino acid sequence consists of VEIKHHHH (SEQ ID NO:9). In some embodiments, the C-terminal amino acid sequence consists of VEIKHHHHH (SEQ ID NO:10). In some embodiments, the C-terminal amino acid sequence consists of VEIKRH (SEQ ID NO:11). In some embodiments, the C-terminal amino acid sequence consists of VEIKRHH (SEQ ID NO:12). In some embodiments, the C-terminal amino acid sequence consists of VEIKRHHH (SEQ ID NO:13). In some embodiments, the C-terminal amino acid sequence consists of VEIKRHHHH (SEQ ID NO:14). In some embodiments, the C-terminal amino acid sequence consists of VEIKRHHHHH (SEQ ID NO: 15). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTH (SEQ ID NO: 16). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTHH (SEQ ID NO: 17). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTHHH (SEQ ID NO: 18). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTHHHH (SEQ ID NO: 19). In some embodiments, the C-terminal amino acid sequence consists of VEIKRTHHHH (SEQ ID NO: 20). In specific embodiments, the multispecific antibody is a trispecific antibody.
[0181] In a specific aspect, a trispecific antibody is provided herein, such as Fig. 10A and Fig. 10BThe antibody shown in, the antibody comprises an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). For example, in some embodiments, the trispecific antibody comprises an Fc-scFv fusion, and the exposed C-terminus fused to the cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) is at the C-terminus of the scFv fusion. In some embodiments, the Fc-scFv fusion further comprises a second scFv having a target binding region different from the first sc-Fv. In some embodiments, the Fc-scFv fusion further comprises a Fab. In some embodiments, a trispecific antibody is provided herein, the trispecific antibody comprising two or more exposed C-termini each fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)). In a specific embodiment, the trispecific antibody includes a target binding domain that is capable of interacting with CD3 on a T cell and an antigen present on the surface of a cancer cell. See, for example, the antigens present on cancer cells in Table 2 below. It should be understood that Fig. 10A and Fig. 10B The antibodies shown in are non-limiting and are exemplary only. In a specific embodiment, the trispecific antibodies are isolated.
[0182] In another aspect, provided herein is a protein (e.g., an antigen binding protein) comprising a non-naturally occurring C-terminus and a (His) n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the present invention provides a protein comprising an antigen binding region of an antibody, wherein the antigen binding region comprises a non-naturally occurring C-terminus and a (His) at the end of the non-naturally occurring C-terminus. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the present invention provides a protein comprising an antibody variable domain, wherein the antibody variable domain comprises a non-naturally occurring C-terminus and a (His) at the end of the non-naturally occurring C-terminus. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the present invention provides a protein comprising an antibody fragment, wherein the antibody fragment comprises a non-naturally occurring C-terminus and a (His) at the end of the non-naturally occurring C-terminus. n(SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In some embodiments, (His) n The n of the sequence is 1. In certain embodiments, (His) n The n of the sequence is 2. In some embodiments, (His) n The n of the sequence is 3. In certain embodiments, (His) n The n of the sequence is 4 (SEQ ID NO: 27). In some embodiments, (His) n The n of the sequence is 5 (SEQ ID NO: 28). In a specific embodiment, the protein is isolated.
[0183] In some embodiments, provided herein is a bispecific antibody comprising an antibody variable domain, wherein the antibody variable domain comprises a non-naturally occurring C-terminus and a (His) at the end of the non-naturally occurring C-terminus. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In certain embodiments, provided herein is a multispecific antibody comprising an antibody variable domain, wherein the antibody variable domain comprises a non-naturally occurring C-terminus and a (His) at the end of the non-naturally occurring C-terminus. n (SEQ ID NO:25) sequence, wherein n is 1, 2, 3, 4 or 5. In certain embodiments, the antibody variable domain is a light chain variable domain. In other embodiments, the antibody variable domain is a heavy chain variable domain. In specific embodiments, the heavy chain variable domain is not camelized. In specific embodiments, the bispecific antibody or multispecific antibody is isolated.
[0184] In certain embodiments, provided herein is a bispecific antibody comprising an antibody fragment, wherein the antibody fragment comprises a non-naturally occurring C-terminus and a (His) at the end of the non-naturally occurring C-terminus. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In some embodiments, a multispecific antibody is provided herein, comprising an antibody fragment, wherein the antibody fragment comprises a non-naturally occurring C-terminus and a (His) at the end of the non-naturally occurring C-terminus. n (SEQ ID NO: 25) sequence, wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the bispecific antibody or multispecific antibody is isolated. In a specific embodiment, the multispecific antibody is trispecific.
[0185] In another aspect, the present invention provides a protein comprising a C-terminal anti-drug antibody epitope and a (His) at the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the present invention provides a protein comprising a C-terminal anti-drug antibody epitope and a (His) at the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the present invention provides a protein comprising an antigen binding region of an antibody, wherein the antigen binding region comprises a C-terminal anti-drug antibody epitope and a (His) at the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the present invention provides a protein comprising an antibody variable region, wherein the antibody variable region comprises a C-terminal anti-drug antibody epitope and a (His) at the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the present invention provides a protein comprising an antibody fragment, wherein the antibody fragment comprises a C-terminal anti-drug antibody epitope and a (His) at the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In some embodiments, (His) n The n of the sequence is 1. In certain embodiments, (His) n The n of the sequence is 2. In some embodiments, (His) n The n of the sequence is 3. In certain embodiments, (His) n The n of the sequence is 4 (SEQ ID NO: 27). In some embodiments, (His) n The n of the sequence is 5 (SEQ ID NO: 28). In a specific embodiment, the protein is isolated.
[0186] In some embodiments, provided herein is a bispecific antibody comprising an antigen binding region of an antibody, wherein the antigen binding region comprises a C-terminal anti-drug antibody epitope and a (His) at the end of the C-terminal anti-drug antibody epitope. n(SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In certain embodiments, provided herein is a multispecific antibody (e.g., a trispecific antibody) comprising an antigen binding region of an antibody, wherein the antigen binding region comprises a C-terminal anti-drug antibody epitope and a (His) at the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25) sequence, wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the bispecific antibody or multispecific antibody is isolated. In a specific embodiment, the multispecific antibody is trispecific.
[0187] In some embodiments, provided herein is a bispecific antibody comprising an antibody variable domain, wherein the antibody variable domain comprises a C-terminal anti-drug antibody epitope and a (His) at the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In certain embodiments, provided herein is a multispecific antibody (e.g., a trispecific antibody) comprising an antibody variable domain, wherein the antibody variable domain comprises a C-terminal anti-drug antibody epitope and a (His) at the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO:25) sequence, wherein n is 1, 2, 3, 4 or 5. In certain embodiments, the antibody variable domain is a light chain variable domain. In other embodiments, the antibody variable domain is a heavy chain variable domain. In specific embodiments, the heavy chain variable domain is not camelized. In specific embodiments, the bispecific antibody or multispecific antibody is isolated. In specific embodiments, the multispecific antibody is trispecific.
[0188] In some embodiments, provided herein is a bispecific antibody comprising an antibody fragment domain, wherein the antibody fragment comprises a C-terminal anti-drug antibody epitope and a (His) at the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In certain embodiments, provided herein is a multispecific antibody (e.g., a trispecific antibody) comprising an antibody fragment, wherein the antibody fragment comprises a C-terminal anti-drug antibody epitope and a (His) at the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25) sequence, wherein n is 1, 2, 3, 4 or 5. In a specific embodiment, the bispecific antibody or multispecific antibody is isolated. In a specific embodiment, the multispecific antibody is trispecific.
[0189] In another aspect, the present invention provides a protein (e.g., a fusion protein or an antigen binding protein) comprising an antibody fragment, wherein the antibody fragment comprises an exposed C-terminus and a (His) at the end of the C-terminus. n (SEQ ID NO: 25), wherein n is 1, 2, 3, 4 or 5. In some embodiments, (His) n The n of the sequence is 1. In certain embodiments, (His) n The n of the sequence is 2. In some embodiments, (His) n The n of the sequence is 3. In certain embodiments, (His) n The n of the sequence is 4 (SEQ ID NO: 27). In some embodiments, (His) n The n of the sequence is 5 (SEQ ID NO: 28). In a specific embodiment, the protein is isolated.
[0190] Without being bound by any theory, in a specific embodiment, a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) or (His) is added to the end of the exposed C-terminus of the polypeptide or protein, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope. n The sequence will change the exposed C-terminus, the non-naturally occurring C-terminus, or the C-terminal anti-drug antibody epitope so that the polypeptide or protein no longer interacts with the reference, or the interaction with the reference is reduced. In some embodiments, the reference is a molecule present in a biological substance. Therefore, in some embodiments, a protein with an exposed C-terminus fused to a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) exhibits reduced interaction with molecules present in biological substances. In some embodiments, biological substances include serum and / or plasma (e.g., human serum and / or human plasma). In specific embodiments, biological substances include serum. In specific embodiments, biological substances include plasma. In specific embodiments, the interaction is determined by an aggregation assay described herein (such as the assay described in Section 7.9.1) or an aggregation assay known to those skilled in the art.
[0191] In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking the cap domain. In some embodiments, the reduction is at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%. In some embodiments, the reduction is at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%. In specific embodiments, the interaction is determined by an immunoassay described herein (such as the assay described in Section 7.9.1) or an immunoassay known to those skilled in the art.
[0192] In some embodiments, the addition of a histidine at the end of an exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking a histidine. In some embodiments, the addition of a histidine at the end of an exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking a histidine by at least about 10%. In some embodiments, the addition of a histidine at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 20% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking a histidine. In some embodiments, the addition of a histidine at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 30% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking a histidine. In some embodiments, the addition of a histidine at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 40% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking a histidine. In some embodiments, the addition of a histidine at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 50% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking a histidine.In some embodiments, the addition of a histidine at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 60% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking a histidine. In some embodiments, the addition of a histidine at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 70% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking a histidine. In some embodiments, the addition of a histidine at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 80% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking a histidine. In some embodiments, the addition of a histidine at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 90% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking a histidine. In some embodiments, the addition of a histidine at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 95% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking a histidine. In some embodiments, the addition of a histidine at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) eliminates the interaction of the polypeptide or protein with a reference. In specific embodiments, the interaction is determined by an immunoassay described herein (such as the assay described in Section 7.9.1) or an immunoassay known to those skilled in the art.
[0193] In some embodiments, the addition of two histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference relative to the interaction of the same reference with the same polypeptide or the same protein lacking two histidines, respectively. In some embodiments, the addition of two histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference relative to the interaction of the same reference with the same polypeptide or the same protein lacking two histidines, respectively, by at least about 10%. In some embodiments, the addition of two histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference by at least about 20% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking two histidines. In some embodiments, the addition of two histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody), the end of the non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference by at least about 30% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking two histidines. In some embodiments, the addition of two histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference by at least about 40% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking two histidines. In some embodiments, the addition of two histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody), the end of the non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference by at least about 50% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking two histidines.In some embodiments, the addition of two histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference by at least about 60% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking two histidines. In some embodiments, the addition of two histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody), the end of the non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference by at least about 70% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking two histidines. In some embodiments, the addition of two histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 80% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking two histidines. In some embodiments, the addition of two histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 90% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking two histidines. In some embodiments, the addition of two histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 95% relative to the interaction of the same reference with the same polypeptide or the same protein lacking two histidines, respectively. In some embodiments, the addition of two histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) eliminates the interaction of the polypeptide or protein with a reference. In specific embodiments, the interaction is determined by an immunoassay described herein (such as the assay described in Section 7.9.1) or an immunoassay known to those skilled in the art.
[0194] In some embodiments, the addition of three histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking three histidines. In some embodiments, the addition of three histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking three histidines, by at least about 10%. In some embodiments, the addition of three histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 20% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking three histidines. In some embodiments, the addition of three histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 30% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking three histidines. In some embodiments, the addition of three histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 40% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking three histidines. In some embodiments, the addition of three histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 50% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking three histidines.In some embodiments, the addition of three histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference by at least about 60% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking three histidines. In some embodiments, the addition of three histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference by at least about 70% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking three histidines. In some embodiments, the addition of three histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 80% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking three histidines. In some embodiments, the addition of three histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 90% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking three histidines. In some embodiments, the addition of three histidines at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 95% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking three histidines. In some embodiments, the addition of three histidines at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) eliminates the interaction of the polypeptide or protein with a reference. In specific embodiments, the interaction is determined by an immunoassay described herein (such as the assay described in Section 7.9.1) or an immunoassay known to those skilled in the art.
[0195] In some embodiments, the addition of four histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking four histidines. In some embodiments, the addition of four histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking four histidines, by at least about 10%. In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 20% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking four histidines. In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 30% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking four histidines. In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 40% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking four histidines. In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 50% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking four histidines.In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 60% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking four histidines. In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 70% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking four histidines. In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 80% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking four histidines. In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 90% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking four histidines. In some embodiments, the addition of four histidines at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 95% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking four histidines. In some embodiments, the addition of four histidines at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) eliminates the interaction of the polypeptide or protein with a reference. In specific embodiments, the interaction is determined by an immunoassay described herein (such as the assay described in Section 7.9.1) or an immunoassay known to those skilled in the art.
[0196] In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference relative to the interaction of the same reference with the same polypeptide or the same protein lacking five histidines, respectively. In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference relative to the interaction of the same reference with the same polypeptide or the same protein lacking five histidines, respectively, by at least about 10%. In some embodiments, the addition of five histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 20% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking five histidines. In some embodiments, the addition of five histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 30% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking five histidines. In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference by at least about 40% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking five histidines. In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference by at least about 50% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking five histidines.In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference by at least about 60% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking five histidines. In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the polypeptide or protein with a reference by at least about 70% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking five histidines. In some embodiments, the addition of five histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 80% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking five histidines. In some embodiments, the addition of five histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 90% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking five histidines. In some embodiments, the addition of five histidines at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces the interaction of the polypeptide or protein with a reference by at least about 95% relative to the interaction of the same reference with the same polypeptide or the same protein, respectively, lacking five histidines. In some embodiments, the addition of five histidines at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) eliminates the interaction of the polypeptide or protein with a reference. In specific embodiments, the interaction is determined by an immunoassay described herein (such as the assay described in Section 7.9.1) or an immunoassay known to those skilled in the art.
[0197] In some embodiments, the reference is a molecule present in a biological substance. In some embodiments, the biological substance includes serum. In some embodiments, the biological substance includes plasma. In some embodiments, the biological substance includes serum and / or plasma (e.g., human serum and / or human plasma). In some embodiments, the reference comprises anti-drug antibodies. In some embodiments, the anti-drug antibodies are pre-existing in the serum and / or plasma of a subject (e.g., a human subject).
[0198] In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA relative to the interaction of the same protein with ADA in the absence of the cap domain. In some embodiments, the reduction is at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%. In some embodiments, the reduction is at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%.
[0199] In some embodiments, a (His) is added to the end of an exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25) sequence (wherein n is 1, 2, 3, 4 or 5) such that the protein interacts with ADA relative to the same protein lacking the (His) n (SEQ ID NO: 25) sequence is used to reduce the interaction with ADA. In some embodiments, (His) is added to the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-natural C-terminus, or the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25) sequence (wherein n is 1, 2, 3, 4 or 5) such that the protein interacts with ADA relative to the same protein lacking the (His) n (SEQ ID NO: 25) sequence, the interaction with ADA is reduced by at least about 10%. In some embodiments, (His) is added to the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-natural C-terminus, or the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25) sequence (wherein n is 1, 2, 3, 4 or 5) such that the protein interacts with ADA relative to the same protein lacking the (His) n(SEQ ID NO: 25) sequence, the interaction with ADA is reduced by at least about 20%. In some embodiments, (His) is added to the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-natural C-terminus, or the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25) sequence (wherein n is 1, 2, 3, 4 or 5) such that the protein interacts with ADA relative to the same protein lacking the (His) n (SEQ ID NO: 25) sequence, the interaction with ADA is reduced by at least about 30%. In some embodiments, (His) is added to the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-natural C-terminus, or the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25) sequence (wherein n is 1, 2, 3, 4 or 5) such that the protein interacts with ADA relative to the same protein lacking the (His) n (SEQ ID NO: 25) sequence, the interaction with ADA is reduced by at least about 40%. In some embodiments, (His) is added to the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-natural C-terminus, or the end of the C-terminal anti-drug antibody epitope. n Sequence (where n is 1, 2, 3, 4 or 5) such that the protein interacts with ADA relative to the same protein lacking the (His) n (SEQ ID NO: 25) sequence, the interaction with ADA is reduced by at least about 50%. In some embodiments, (His) is added to the end of the exposed C-terminus of the therapeutic protein (e.g., antigen binding protein), the end of the non-natural C-terminus, or the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25) sequence (wherein n is 1, 2, 3, 4 or 5) such that the protein interacts with ADA relative to the same protein lacking the (His) n (SEQ ID NO: 25) sequence, the interaction with ADA is reduced by at least about 60%. In some embodiments, (His) is added to the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-natural C-terminus, or the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25) sequence (wherein n is 1, 2, 3, 4 or 5) such that the protein interacts with ADA relative to the same protein lacking the (His) n(SEQ ID NO: 25) sequence, the interaction with ADA is reduced by at least about 70%. In some embodiments, (His) is added to the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-natural C-terminus, or the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25) sequence (wherein n is 1, 2, 3, 4 or 5) such that the protein interacts with ADA relative to the same protein lacking the (His) n (SEQ ID NO: 25) sequence, the interaction with ADA is reduced by at least about 80%. In some embodiments, (His) is added to the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-natural C-terminus, or the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25) sequence (wherein n is 1, 2, 3, 4 or 5) such that the protein interacts with ADA relative to the same protein lacking the (His) n (SEQ ID NO: 25) sequence, the interaction with ADA is reduced by at least about 90%. In some embodiments, (His) is added to the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-natural C-terminus, or the end of the C-terminal anti-drug antibody epitope. n (SEQ ID NO: 25) sequence (wherein n is 1, 2, 3, 4 or 5) such that the protein interacts with ADA relative to the same protein lacking the (His) n (SEQ ID NO: 25) sequence, the interaction with ADA is reduced by at least about 95%. Various assays known to those skilled in the art or described herein can be used to measure and / or detect the interaction of proteins with ADA, such as the assay described in Section 7.9.1. In a specific embodiment, the interaction between the protein and ADA is determined by ELISA, surface plasmon resonance assay (e.g., BIACORE), electrochemiluminescence (ECL)-based assays, or other immunoassays described herein or known to those skilled in the art.
[0200] In specific embodiments, the addition of a single histidine at the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA relative to the interaction of the same protein with ADA in the absence of the single histidine. In some embodiments, the addition of a single histidine at the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 10% relative to the interaction of the same protein with ADA in the absence of the single histidine. In some embodiments, the addition of a single histidine at the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 20% relative to the interaction of the same protein with ADA in the absence of the single histidine. In some embodiments, the addition of a single histidine at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 30% relative to the interaction of the same protein with ADA in the absence of the single histidine. In some embodiments, the addition of a single histidine at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 40% relative to the interaction of the same protein with ADA in the absence of the single histidine. In some embodiments, the addition of a single histidine at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 50% relative to the interaction of the same protein with ADA in the absence of the single histidine. In some embodiments, the addition of a single histidine at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 60% relative to the interaction of the same protein with ADA in the absence of the single histidine. In some embodiments, the addition of a single histidine at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 70% relative to the interaction of the same protein with ADA in the absence of the single histidine.In some embodiments, the addition of a single histidine at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 80% relative to the interaction of the same protein with ADA in the absence of the single histidine. In some embodiments, the addition of a single histidine at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 90% relative to the interaction of the same protein with ADA in the absence of the single histidine. In some embodiments, the addition of a single histidine at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 95% relative to the interaction of the same protein with ADA in the absence of the single histidine. In a specific embodiment, the addition of a single histidine at the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope eliminates the interaction of the protein with ADA. Various assays known to those skilled in the art or described herein can be used to measure and / or detect the interaction of proteins with ADA, such as the assays described in Section 7.9.1. In a specific embodiment, the interaction between the protein and ADA is determined by ELISA, surface plasmon resonance assays (e.g., BIACORE), or other immunoassays described herein or known to those skilled in the art.
[0201] In a specific embodiment, two histidines are added to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope so that the interaction of the protein with ADA is reduced relative to the interaction of the same protein with ADA when two histidines are missing. In some embodiments, two histidines are added to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope so that the interaction of the protein with ADA is reduced by at least about 10% relative to the interaction of the same protein with ADA when two histidines are missing. In some embodiments, two histidines are added to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope so that the interaction of the protein with ADA is reduced by at least about 20% relative to the interaction of the same protein with ADA when two histidines are missing. In some embodiments, adding two histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 30% relative to the interaction of the same protein with ADA when two histidines are missing. In some embodiments, adding two histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 40% relative to the interaction of the same protein with ADA when two histidines are missing. In some embodiments, adding two histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 50% relative to the interaction of the same protein with ADA when two histidines are missing. In some embodiments, the addition of two histidines at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 60% relative to the interaction of the same protein with ADA in the absence of two histidines. In some embodiments, the addition of two histidines at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 70% relative to the interaction of the same protein with ADA in the absence of two histidines.In some embodiments, adding two histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 80% relative to the interaction of the same protein with ADA when two histidines are missing. In some embodiments, adding two histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 90% relative to the interaction of the same protein with ADA when two histidines are missing. In some embodiments, adding two histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 95% relative to the interaction of the same protein with ADA when two histidines are missing. In a specific embodiment, adding two histidines at the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope eliminates the interaction of the protein with ADA. Various assays known to those skilled in the art or described herein can be used to measure and / or detect the interaction of proteins with ADA, such as the assays described in Section 7.9.1. In a specific embodiment, the interaction between the protein and ADA is determined by ELISA, surface plasmon resonance assays (e.g., BIACORE), or other immunoassays described herein or known to those skilled in the art.
[0202] In a specific embodiment, three histidines are added to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope so that the interaction of the protein with ADA is reduced relative to the interaction of the same protein with ADA when the three histidines are missing. In some embodiments, three histidines are added to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope so that the interaction of the protein with ADA is reduced by at least about 10% relative to the interaction of the same protein with ADA when the three histidines are missing. In some embodiments, three histidines are added to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope so that the interaction of the protein with ADA is reduced by at least about 20% relative to the interaction of the same protein with ADA when the three histidines are missing. In some embodiments, adding three histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 30% relative to the interaction of the same protein with ADA when the three histidines are missing. In some embodiments, adding three histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 40% relative to the interaction of the same protein with ADA when the three histidines are missing. In some embodiments, adding three histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 50% relative to the interaction of the same protein with ADA when the three histidines are missing. In some embodiments, the addition of three histidines at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 60% relative to the interaction of the same protein with ADA in the absence of three histidines. In some embodiments, the addition of three histidines at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 70% relative to the interaction of the same protein with ADA in the absence of three histidines.In some embodiments, adding three histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 80% relative to the interaction of the same protein with ADA when the three histidines are missing. In some embodiments, adding three histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 90% relative to the interaction of the same protein with ADA when the three histidines are missing. In some embodiments, adding three histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 95% relative to the interaction of the same protein with ADA when the three histidines are missing. In a specific embodiment, the addition of three histidines at the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope eliminates the interaction of the protein with ADA. Various assays known to those skilled in the art or described herein can be used to measure and / or detect the interaction of proteins with ADA, such as the assays described in Section 7.9.1. In a specific embodiment, the interaction between the protein and ADA is determined by ELISA, surface plasmon resonance assays (e.g., BIACORE), or other immunoassays described herein or known to those skilled in the art.
[0203] In a specific embodiment, adding four histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA relative to the interaction of the same protein with ADA when four histidines are missing. In some embodiments, adding four histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 10% relative to the interaction of the same protein with ADA when four histidines are missing. In some embodiments, adding four histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 20% relative to the interaction of the same protein with ADA when four histidines are missing. In some embodiments, adding four histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 30% relative to the interaction of the same protein with ADA when the four histidines are missing. In some embodiments, adding four histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 40% relative to the interaction of the same protein with ADA when the four histidines are missing. In some embodiments, adding four histidines to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 50% relative to the interaction of the same protein with ADA when the four histidines are missing. In some embodiments, the addition of four histidines at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 60% relative to the interaction of the same protein with ADA in the absence of four histidines. In some embodiments, the addition of four histidines at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 70% relative to the interaction of the same protein with ADA in the absence of four histidines.In some embodiments, the addition of four histidines at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 80% relative to the interaction of the same protein with ADA when the four histidines are missing. In some embodiments, the addition of four histidines at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 90% relative to the interaction of the same protein with ADA when the four histidines are missing. In some embodiments, the addition of four histidines at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 95% relative to the interaction of the same protein with ADA when the four histidines are missing. In a specific embodiment, adding four histidines to the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope eliminates the interaction of the protein with ADA. Various assays known to those skilled in the art or described herein can be used to measure and / or detect the interaction of proteins with ADA, such as the assays described in Section 7.9.1. In a specific embodiment, the interaction between the protein and ADA is determined by ELISA, surface plasmon resonance assays (e.g., BIACORE), or other immunoassays described herein or known to those skilled in the art.
[0204] In a specific embodiment, five histidines are added to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope so that the interaction of the protein with ADA is reduced relative to the interaction of the same protein with ADA when the five histidines are missing. In some embodiments, five histidines are added to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope so that the interaction of the protein with ADA is reduced by at least about 10% relative to the interaction of the same protein with ADA when the five histidines are missing. In some embodiments, five histidines are added to the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope so that the interaction of the protein with ADA is reduced by at least about 20% relative to the interaction of the same protein with ADA when the five histidines are missing. In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 30% relative to the interaction of the same protein with ADA when the five histidines are missing. In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 40% relative to the interaction of the same protein with ADA when the five histidines are missing. In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 50% relative to the interaction of the same protein with ADA when the five histidines are missing. In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 60% relative to the interaction of the same protein with ADA in the absence of five histidines. In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a protein (e.g., an antigen binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 70% relative to the interaction of the same protein with ADA in the absence of five histidines.In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 80% relative to the interaction of the same protein with ADA in the absence of five histidines. In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 90% relative to the interaction of the same protein with ADA in the absence of five histidines. In some embodiments, the addition of five histidines at the end of the exposed C-terminus of a protein (e.g., an antigen-binding protein), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the interaction of the protein with ADA by at least about 95% relative to the interaction of the same protein with ADA in the absence of five histidines. In a specific embodiment, the addition of five histidines at the end of the exposed C-terminus of the protein (e.g., antigen binding protein), the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope eliminates the interaction of the protein with ADA. Various assays known to those skilled in the art or described herein can be used to measure and / or detect the interaction of proteins with ADA, such as the assays described in Section 7.9.1. In a specific embodiment, the interaction between the protein and ADA is determined by ELISA, surface plasmon resonance assays (e.g., BIACORE), or other immunoassays described herein or known to those skilled in the art.
[0205] In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively, when incubated with a biological substance. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by at least about 10% relative to the aggregation exhibited by the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively, when incubated with a biological substance. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by at least about 20% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively, when incubated with a biological substance.In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by at least about 30% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively, when incubated with a biological substance. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by at least about 40% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively, when incubated with a biological substance. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by at least about 50% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively, when incubated with a biological substance.In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by at least about 60% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively, when incubated with a biological substance. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by at least about 70% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively, when incubated with a biological substance. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by at least about 80% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively, when incubated with a biological substance.In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by at least about 90% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively, when incubated with a biological substance. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by at least about 95% relative to the aggregation exhibited by the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37) respectively when incubated with a biological substance. In specific embodiments, aggregation is determined by an aggregation assay described herein (such as the assay described in Section 7.9.7) or an aggregation assay known to those of skill in the art.
[0206] In some embodiments, the addition of a histidine to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance relative to the aggregation exhibited when the same polypeptide or the same protein lacking a histidine is incubated with the biological substance. In some embodiments, the addition of a histidine to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance relative to the aggregation exhibited when the same polypeptide or the same protein lacking a histidine is incubated with the biological substance by about 10%. In some embodiments, the addition of a histidine to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 20% relative to the aggregation exhibited by the same polypeptide or the same protein lacking a histidine when incubated with the biological substance. In some embodiments, the addition of a histidine to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 30% relative to the aggregation exhibited by the same polypeptide or the same protein lacking a histidine when incubated with the biological substance. In some embodiments, the addition of a histidine to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 40% relative to the aggregation exhibited by the same polypeptide or the same protein lacking a histidine when incubated with the biological substance. In some embodiments, the addition of a histidine to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 50% relative to the aggregation exhibited by the same polypeptide or the same protein lacking a histidine when incubated with the biological substance.In some embodiments, the addition of a histidine to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation by about 60% when incubated with a biological substance relative to the aggregation exhibited by the same polypeptide or the same protein lacking a histidine when incubated with the biological substance. In some embodiments, the addition of a histidine to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation by about 70% when incubated with a biological substance relative to the aggregation exhibited by the same polypeptide or the same protein lacking a histidine when incubated with the biological substance. In some embodiments, the addition of a histidine to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 80% relative to the aggregation exhibited by the same polypeptide or the same protein lacking a histidine when incubated with the biological substance. In some embodiments, the addition of a histidine to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 90% relative to the aggregation exhibited by the same polypeptide or the same protein lacking a histidine when incubated with the biological substance. In some embodiments, the addition of one histidine at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 95% relative to the aggregation exhibited by the same polypeptide or the same protein, respectively lacking one histidine, when incubated with the biological substance. In specific embodiments, aggregation is determined by an aggregation assay described herein (such as the assay described in Section 7.9.7) or an aggregation assay known to those skilled in the art. In some embodiments, the addition of two histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance relative to the aggregation exhibited by the same polypeptide or the same protein, respectively lacking two histidines, when incubated with the biological substance. In specific embodiments, aggregation is determined by an aggregation assay described herein (such as the assay described in Section 7.9.7) or an aggregation assay known to those skilled in the art.
[0207] In some embodiments, adding two histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 10% relative to the aggregation exhibited when the same polypeptide or the same protein lacking two histidines is incubated with the biological substance. In some embodiments, adding two histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 20% relative to the aggregation exhibited when the same polypeptide or the same protein lacking two histidines is incubated with the biological substance. In some embodiments, adding two histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 30% relative to the aggregation exhibited when the same polypeptide or the same protein lacking two histidines is incubated with the biological substance. In some embodiments, adding two histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 40% relative to the aggregation exhibited when the same polypeptide or the same protein lacking two histidines is incubated with the biological substance. In some embodiments, adding two histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 50% relative to the aggregation exhibited when the same polypeptide or the same protein lacking two histidines is incubated with the biological substance. In some embodiments, adding two histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 60% relative to the aggregation exhibited when the same polypeptide or the same protein lacking two histidines is incubated with the biological substance.In some embodiments, adding two histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 70% relative to the aggregation exhibited when the same polypeptide or the same protein lacking two histidines is incubated with the biological substance. In some embodiments, adding two histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 80% relative to the aggregation exhibited when the same polypeptide or the same protein lacking two histidines is incubated with the biological substance. In some embodiments, the addition of two histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 90% relative to the aggregation exhibited by the same polypeptide or the same protein lacking two histidines when incubated with the biological substance. In some embodiments, the addition of two histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 95% relative to the aggregation exhibited by the same polypeptide or the same protein lacking two histidines when incubated with the biological substance. In specific embodiments, aggregation is determined by an aggregation assay described herein (such as the assay described in Section 7.9.7) or an aggregation assay known to those skilled in the art.
[0208] In some embodiments, the addition of three histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance relative to the same polypeptide or the same protein lacking three histidines, respectively, when incubated with the biological substance. In some embodiments, the addition of three histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance relative to the aggregation exhibited by the same polypeptide or the same protein lacking three histidines, respectively, when incubated with the biological substance, by about 10%. In some embodiments, the addition of three histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 20% relative to the aggregation exhibited when the same polypeptide or the same protein lacking three histidines is incubated with the biological substance. In some embodiments, the addition of three histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 30% relative to the aggregation exhibited when the same polypeptide or the same protein lacking three histidines is incubated with the biological substance. In some embodiments, the addition of three histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 40% relative to the aggregation exhibited when the same polypeptide or the same protein lacking three histidines is incubated with the biological substance. In some embodiments, the addition of three histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 50% relative to the aggregation exhibited when the same polypeptide or the same protein lacking three histidines is incubated with the biological substance.In some embodiments, the addition of three histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 60% relative to the aggregation exhibited when the same polypeptide or the same protein lacking three histidines is incubated with the biological substance. In some embodiments, the addition of three histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 70% relative to the aggregation exhibited when the same polypeptide or the same protein lacking three histidines is incubated with the biological substance. In some embodiments, the addition of three histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 80% relative to the aggregation exhibited when the same polypeptide or the same protein lacking three histidines is incubated with the biological substance. In some embodiments, the addition of three histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 90% relative to the aggregation exhibited when the same polypeptide or the same protein lacking three histidines is incubated with the biological substance. In some embodiments, the addition of three histidines at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 95% relative to the aggregation exhibited when the same polypeptide or the same protein lacking three histidines is incubated with the biological substance. In specific embodiments, aggregation is determined by an aggregation assay described herein (such as the assay described in Section 7.9.7) or an aggregation assay known to those skilled in the art.
[0209] In some embodiments, the addition of four histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance relative to the same polypeptide or the same protein lacking four histidines, respectively, when incubated with the biological substance. In some embodiments, the addition of four histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance relative to the aggregation exhibited by the same polypeptide or the same protein lacking four histidines, respectively, when incubated with the biological substance, by about 10%. In some embodiments, the addition of four histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 20% relative to the aggregation exhibited when the same polypeptide or the same protein lacking four histidines is incubated with the biological substance. In some embodiments, the addition of four histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 30% relative to the aggregation exhibited when the same polypeptide or the same protein lacking four histidines is incubated with the biological substance. In some embodiments, the addition of four histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 40% relative to the aggregation exhibited when the same polypeptide or the same protein lacking four histidines is incubated with the biological substance. In some embodiments, the addition of four histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 50% relative to the aggregation exhibited when the same polypeptide or the same protein lacking four histidines is incubated with the biological substance.In some embodiments, the addition of four histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 60% relative to the aggregation exhibited by the same polypeptide or the same protein lacking four histidines when incubated with the biological substance. In some embodiments, the addition of four histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 70% relative to the aggregation exhibited by the same polypeptide or the same protein lacking four histidines when incubated with the biological substance. In some embodiments, the addition of four histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 80% relative to the aggregation exhibited when the same polypeptide or the same protein lacking four histidines is incubated with the biological substance. In some embodiments, the addition of four histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 90% relative to the aggregation exhibited when the same polypeptide or the same protein lacking four histidines is incubated with the biological substance. In some embodiments, the addition of four histidines at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 95% relative to the aggregation exhibited when the same polypeptide or the same protein lacking four histidines is incubated with the biological substance. In specific embodiments, aggregation is determined by an aggregation assay described herein (such as the assay described in Section 7.9.7) or an aggregation assay known to those skilled in the art.
[0210] In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance relative to the aggregation exhibited when the same polypeptide or the same protein lacking five histidines is incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance relative to the aggregation exhibited when the same polypeptide or the same protein lacking five histidines is incubated with the biological substance by about 10%. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 20% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 30% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 40% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 50% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance.In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 60% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 70% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 80% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 90% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines at the end of an exposed C-terminus, a non-naturally occurring C-terminus, or a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 95% relative to the aggregation exhibited when the same polypeptide or the same protein lacking five histidines is incubated with the biological substance. In specific embodiments, self-aggregation is determined by an aggregation assay described herein (such as the assay described in Section 7.9.7) or an aggregation assay known to those skilled in the art.
[0211] In specific embodiments, the addition of four histidines to the end of the exposed C-terminus of a polypeptide, protein (e.g., antibody), bispecific antibody, or multispecific antibody (e.g., trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the self-aggregation of the polypeptide, protein (e.g., antibody), bispecific antibody, or multispecific antibody relative to the same polypeptide, protein (e.g., antibody), bispecific antibody, or multispecific antibody (e.g., trispecific antibody) that lacks four histidines, respectively. In some embodiments, the addition of four histidines to the end of the exposed C-terminus of a protein (e.g., antibody), bispecific antibody, or multispecific antibody (e.g., trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the self-aggregation of the polypeptide, protein (e.g., antibody), bispecific antibody, or multispecific antibody (e.g., trispecific antibody) relative to the self-aggregation of the same protein (e.g., antibody), bispecific antibody, or multispecific antibody (e.g., trispecific antibody) that lacks four histidines, respectively. In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a protein (e.g., antibody), bispecific antibody, or multispecific antibody (e.g., trispecific antibody) reduces the self-aggregation of the polypeptide, the protein (e.g., antibody), the bispecific antibody, or the multispecific antibody (e.g., trispecific antibody) by at least about 20% relative to the self-aggregation of the same protein (e.g., antibody), the same bispecific antibody, or the same multispecific antibody (e.g., trispecific antibody) lacking four histidines, respectively. In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a protein (e.g., antibody), the bispecific antibody, or the multispecific antibody (e.g., trispecific antibody) reduces the self-aggregation of the polypeptide, the protein (e.g., antibody), the bispecific antibody, or the multispecific antibody (e.g., trispecific antibody) by at least about 30% relative to the self-aggregation of the same protein (e.g., antibody), the same bispecific antibody, or the same multispecific antibody (e.g., trispecific antibody) lacking four histidines, respectively. In some embodiments, the addition of four histidines to the end of the exposed C-terminus, the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope of a protein (e.g., antibody), bispecific antibody, or multispecific antibody (e.g., trispecific antibody) reduces self-aggregation of the polypeptide, the protein (e.g., antibody), the bispecific antibody, or the multispecific antibody (e.g., trispecific antibody) by at least about 40% relative to the self-aggregation of the same protein (e.g., antibody), the same bispecific antibody, or the same multispecific antibody (e.g., trispecific antibody), respectively, lacking the four histidines.In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a protein (e.g., antibody), bispecific antibody, or multispecific antibody (e.g., trispecific antibody) reduces the self-aggregation of the polypeptide, the protein (e.g., antibody), the bispecific antibody, or the multispecific antibody (e.g., trispecific antibody) by at least about 50% relative to the self-aggregation of the same protein (e.g., antibody), the same bispecific antibody, or the same multispecific antibody (e.g., trispecific antibody) lacking four histidines, respectively. In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a protein (e.g., antibody), the bispecific antibody, or the multispecific antibody (e.g., trispecific antibody) reduces the self-aggregation of the polypeptide, the protein (e.g., antibody), the bispecific antibody, or the multispecific antibody (e.g., trispecific antibody) by at least about 60% relative to the self-aggregation of the same protein (e.g., antibody), the same bispecific antibody, or the same multispecific antibody (e.g., trispecific antibody) lacking four histidines, respectively. In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a protein (e.g., antibody), bispecific antibody, or multispecific antibody (e.g., trispecific antibody) reduces the self-aggregation of the polypeptide, the protein (e.g., antibody), the bispecific antibody, or the multispecific antibody (e.g., trispecific antibody) by at least about 70% relative to the self-aggregation of the same protein (e.g., antibody), the same bispecific antibody, or the same multispecific antibody (e.g., trispecific antibody) lacking four histidines, respectively. In some embodiments, the addition of four histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a protein (e.g., antibody), the bispecific antibody, or the multispecific antibody (e.g., trispecific antibody) reduces the self-aggregation of the polypeptide, the protein (e.g., antibody), the bispecific antibody, or the multispecific antibody (e.g., trispecific antibody) by at least about 80% relative to the self-aggregation of the same protein (e.g., antibody), the same bispecific antibody, or the same multispecific antibody (e.g., trispecific antibody) lacking four histidines, respectively. In some embodiments, the addition of four histidines to the end of the exposed C-terminus, the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope of a protein (e.g., antibody), bispecific antibody, or multispecific antibody (e.g., trispecific antibody) reduces self-aggregation of the polypeptide, the protein (e.g., antibody), the bispecific antibody, or the multispecific antibody (e.g., trispecific antibody) by at least about 90% relative to the same protein (e.g., antibody), the same bispecific antibody, or the same multispecific antibody (e.g., trispecific antibody), respectively, lacking the four histidines.In some embodiments, the addition of four histidines at the end of the exposed C-terminus of a protein (e.g., an antibody), a bispecific antibody, or a multispecific antibody (e.g., a trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces the self-aggregation of the polypeptide, the protein (e.g., an antibody), the bispecific antibody, or the multispecific antibody (e.g., a trispecific antibody) by at least about 95% relative to the self-aggregation of the same protein (e.g., an antibody), the same bispecific antibody, or the same multispecific antibody (e.g., a trispecific antibody) that lacks four histidines, respectively. In specific embodiments, the addition of four histidines at the end of the exposed C-terminus of a protein (e.g., an antibody), a bispecific antibody, or a multispecific antibody (e.g., a trispecific antibody), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope eliminates the aggregation of the polypeptide, the protein (e.g., an antibody), the bispecific antibody, or the multispecific antibody. In specific embodiments, self-aggregation is determined by an aggregation assay described herein (such as the assay described in Section 7.9.7) or an aggregation assay known to those skilled in the art.
[0212] In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance relative to the aggregation exhibited when the same polypeptide or the same protein lacking five histidines is incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance relative to the aggregation exhibited when the same polypeptide or the same protein lacking five histidines is incubated with the biological substance by about 10%. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 20% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 30% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 40% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 50% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance.In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 60% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 70% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 80% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines to the end of the exposed C-terminus of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)), the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope reduces aggregation when incubated with a biological substance by about 90% relative to the aggregation exhibited by the same polypeptide or the same protein lacking five histidines when incubated with the biological substance. In some embodiments, the addition of five histidines at the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces aggregation when incubated with a biological substance by about 95% relative to the aggregation exhibited when the same polypeptide or the same protein lacking five histidines is incubated with the biological substance. In specific embodiments, aggregation is determined by an aggregation assay described herein (such as the assay described in Section 7.9.7) or an aggregation assay known to those skilled in the art.
[0213] In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) results in reduced self-aggregation relative to the same polypeptide or the same protein lacking a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces self-aggregation by at least about 10% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces self-aggregation by at least about 20% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces self-aggregation by at least about 30% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively.In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces self-aggregation by at least about 40% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces self-aggregation by at least about 50% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces self-aggregation by at least about 60% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces self-aggregation by at least about 70% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively.In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of a non-naturally occurring C-terminus, or the end of a C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces self-aggregation by at least about 80% relative to the same polypeptide or the same protein lacking the cap domain (e.g., His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)), respectively. In some embodiments, the addition of a cap domain (e.g., a His cap domain, SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37)) to the end of the exposed C-terminus, the end of the non-naturally occurring C-terminus, or the end of the C-terminal anti-drug antibody epitope of a polypeptide or protein (e.g., an antibody such as a bispecific antibody or a multispecific antibody (e.g., a trispecific antibody)) reduces self-aggregation by at least about 90% relative to the same polypeptide or th...
Claims
1. An isolated polypeptide comprising one or more target binding regions and an exposed C-terminus fused to a cap domain, wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37), and wherein the isolated polypeptide exhibits a reduced interaction with a reference substance relative to the interaction of the isolated polypeptide with the reference substance in the absence of the cap domain.
2. The isolated polypeptide according to claim 1, wherein the reference substance is a molecule present in a biological substance.
3. The isolated polypeptide according to claim 2, wherein the biological substance comprises serum and / or plasma.
4. The isolated polypeptide according to any one of claims 1 to 3, wherein the reference comprises anti-drug antibodies, optionally the anti-drug antibodies pre-exist in the serum and / or plasma of a subject.
5. The isolated polypeptide according to any one of claims 1 to 4, wherein the interaction with the reference substance is determined by an immunoassay.
6. The isolated polypeptide according to any one of claims 1 to 4, wherein the interaction with the reference substance is assessed in vitro or in vivo.
7. An isolated polypeptide comprising one or more target binding regions and an exposed C-terminus fused to a cap domain, wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37), and wherein the isolated polypeptide exhibits reduced self-aggregation under the same conditions relative to the self-aggregation exhibited by the isolated polypeptide in the absence of the cap domain.
8. The isolated polypeptide according to claim 7, wherein self-aggregation is reduced in a high concentration liquid formulation (HCLF).
9. The isolated polypeptide of claim 8, wherein the HCLF concentration comprises about 50 mg / mL to about 150 mg / mL of the isolated polypeptide.
10. The isolated polypeptide according to any one of claims 7 to 9, wherein self-aggregation is reduced under heat stress.
11. The isolated polypeptide of claim 10, wherein the heat stress comprises incubation at 40°C for about two weeks.
12. The isolated polypeptide according to any one of claims 7 to 11, wherein the self-aggregation is assessed by size exclusion chromatography.
13. An isolated polypeptide comprising one or more target binding regions and an exposed C-terminus fused to a cap domain, wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37), and wherein the isolated polypeptide exhibits reduced aggregation when incubated with a biological agent relative to the aggregation exhibited by the isolated polypeptide when incubated with the biological agent in the absence of the cap domain.
14. The isolated polypeptide according to claim 13, wherein the biological substance is human serum and / or human plasma.
15. The isolated polypeptide of claim 14, wherein incubating with the biological substance comprises: (a) incubating at about 37°C for about 2 days to about 5 days, about 2 days to about 7 days, or about 5 days to about 14 days; (b) incubating at about 40°C for about 2 days to about 5 days, about 2 days to about 7 days, or about 7 days to about 14 days; (c) incubating at about 4°C for about 2 days to about 5 days, about 2 days to about 7 days, or about 7 days to about 14 days; or (d) incubating at about 25°C for about 7 days to about 14 days.
16. The isolated polypeptide according to any one of claims 13 to 15, wherein the biological substance comprises anti-drug antibodies, optionally the anti-drug antibodies are pre-existing in the serum and / or plasma of a subject.
17. The isolated polypeptide according to any one of claims 1 to 16, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
18. The isolated polypeptide of any one of claims 1 to 17, wherein the one or more target binding regions comprise an antibody variable domain or an antigen binding fragment thereof.
19. The isolated polypeptide of any one of claims 1 to 17, wherein the one or more target binding regions comprise a light chain antibody variable domain or an antigen binding fragment thereof and / or a heavy antibody variable domain or an antigen binding fragment thereof.
20. The isolated polypeptide according to any one of claims 1 to 19, wherein the His cap domain consists of a single histidine residue, two histidine residues, three histidine residues, four histidine residues (SEQ ID NO: 27) or five histidine residues (SEQ ID NO: 28).
21. The isolated polypeptide according to any one of claims 1 to 18, wherein the exposed C-terminus fused to the His cap domain consists of: (a) an amino acid sequence selected from the group consisting of VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4), and VTVSSHHHHH (SEQ ID NO: 5); (b) an amino acid sequence selected from the group consisting of VEIKH (SEQ ID NO:6), VEIKHH (SEQ ID NO:7), VEIKHHH (SEQ ID NO:8), VEIKHHHH (SEQ ID NO:9) and VEIKHHHHH (SEQ ID NO:10); (c) an amino acid sequence selected from the group consisting of VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14) and VEIKRHHHHH (SEQ ID NO: 15); (d) an amino acid sequence selected from the group consisting of VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHH (SEQ ID NO: 19), and VEIKRTHHHHH (SEQ ID NO: 20); or (e) the amino acid sequence of TKVTVL(His)n (SEQ ID NO:46), TKLTVL(His)n (SEQ ID NO:47), TQLIIL(His)n (SEQ ID NO:48), TELTVL(His)n (SEQ ID NO:49) or TQLTVL(His)n (SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.
22. An isolated protein, comprising: (a) a first polypeptide comprising a target binding region and an exposed C-terminus fused to a cap domain, wherein the cap domain is a His cap domain, or consists of an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37); and (b) a second polypeptide, the second polypeptide comprising a target binding region, wherein the isolated protein exhibits a reduced interaction with a reference relative to the interaction of the isolated protein with the reference in the absence of the cap domain.
23. The isolated protein of claim 22, wherein the target binding regions of the first polypeptide and the second polypeptide are capable of binding to different targets.
24. The isolated protein of claim 22 or 23, wherein the exposed C-terminus of the first polypeptide comprises an anti-drug antibody epitope.
25. The isolated protein of any one of claims 22 to 24, wherein the target binding region of the second polypeptide comprises an antibody variable domain or an antigen binding fragment thereof.
26. The isolated protein of any one of claims 22 to 24, wherein the target binding region of the second polypeptide comprises a light chain antibody variable domain or an antigen binding fragment thereof and / or a heavy chain antibody variable domain or an antigen binding fragment thereof.
27. The isolated protein of any one of claims 22 to 26, wherein the second polypeptide comprises an exposed C-terminus fused to a cap domain, wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36), TVAPTESS (SEQ ID NO: 37), HHHHHH (SEQ ID NO: 26), or AS.
28. The isolated protein of claim 27, wherein the exposed C-terminus of the second polypeptide comprises an anti-drug antibody epitope.
29. The isolated protein of claim 27 or 28, wherein the His cap domain of the second polypeptide consists of a single histidine residue, two histidine residues, three histidine residues, four histidine residues (SEQ ID NO: 27) or five histidine residues (SEQ ID NO: 28).
30. The isolated protein of claim 27 or 28, wherein the exposed C-terminus fused to the His cap domain of the second polypeptide consists of an amino acid sequence selected from the group consisting of: (a) VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4) and VTVSSHHHHH (SEQ ID NO: 5); (b) VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9) and VEIKHHHHH (SEQ ID NO: 10); (c) VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14) and VEIKRHHHHH (SEQ ID NO: 15); (d) VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHHH (SEQ ID NO: 19) and VEIKRTHHHHH (SEQ ID NO: 20); or (e) the amino acid sequence of TKVTVL(His)n (SEQ ID NO:46), TKLTVL(His)n (SEQ ID NO:47), TQLIIL(His)n (SEQ ID NO:48), TELTVL(His)n (SEQ ID NO:49) or TQLTVL(His)n (SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.
31. The isolated protein of any one of claims 22 to 30, wherein the target binding region of the first polypeptide comprises an antibody variable domain or an antigen binding fragment thereof.
32. The isolated protein of any one of claims 22 to 30, wherein the target binding region of the first polypeptide comprises a light chain antibody variable domain or an antigen binding fragment thereof and / or a heavy chain antibody variable domain or an antigen binding fragment thereof.
33. The isolated protein of any one of claims 22 to 32, wherein the His cap domain of the first polypeptide consists of a single histidine residue, two histidine residues, three histidine residues, four histidine residues (SEQ ID NO: 27) or five histidine residues (SEQ ID NO: 28).
34. The isolated protein of any one of claims 22 to 31, wherein the exposed C-terminus fused to the His cap domain of the first polypeptide consists of an amino acid sequence selected from the group consisting of: (a) VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4) and VTVSSHHHHH (SEQ ID NO: 5); (b) VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9) and VEIKHHHHH (SEQ ID NO: 10); (c) VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14) and VEIKRHHHHH (SEQ ID NO: 15); (d) VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHHH (SEQ ID NO: 19) and VEIKRTHHHHH (SEQ ID NO: 20); or (e) the amino acid sequence of TKVTVL(His)n (SEQ ID NO:46), TKLTVL(His)n (SEQ ID NO:47), TQLIIL(His)n (SEQ ID NO:48), TELTVL(His)n (SEQ ID NO:49) or TQLTVL(His)n (SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.
35. The isolated protein of any one of claims 22 to 34, wherein the isolated protein further comprises a third polypeptide comprising a target binding region.
36. The isolated protein of claim 35, wherein the third polypeptide is capable of binding to a target different from the first polypeptide, the second polypeptide, or both.
37. The isolated protein of claim 35 or 36, wherein the target binding region of the third polypeptide comprises an antibody variable domain or an antigen binding fragment thereof.
38. The isolated protein of claim 35 or 36, wherein the target binding region of the third polypeptide comprises a light chain antibody variable domain or an antigen binding fragment thereof and / or a heavy chain antibody variable domain or an antigen binding fragment thereof.
39. The isolated protein of any one of claims 35 to 38, wherein the third polypeptide comprises an exposed C-terminus fused to a cap domain, wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36), TVAPTESS (SEQ ID NO: 37), HHHHHH (SEQ ID NO: 26), or AS.
40. The isolated protein of claim 39, wherein the exposed C-terminus of the third polypeptide comprises an anti-drug antibody epitope.
41. The isolated protein of claim 39 or 40, wherein the His cap domain of the third polypeptide consists of a single histidine residue, two histidine residues, three histidine residues, four histidine residues (SEQ ID NO: 27) or five histidine residues (SEQ ID NO: 28).
42. The isolated protein of claim 39 or 40, wherein the exposed C-terminus of the third polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of: (a) VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4) and VTVSSHHHHH (SEQ ID NO: 5); (b) VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9) and VEIKHHHHH (SEQ ID NO: 10); (c) VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14) and VEIKRHHHHH (SEQ ID NO: 15); (d) VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHHH (SEQ ID NO: 19) and VEIKRTHHHHH (SEQ ID NO: 20); or (e) the amino acid sequence of TKVTVL(His)n (SEQ ID NO:46), TKLTVL(His)n (SEQ ID NO:47), TQLIIL(His)n (SEQ ID NO:48), TELTVL(His)n (SEQ ID NO:49) or TQLTVL(His)n (SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.
43. The isolated protein of any one of claims 22 to 42, wherein the isolated protein is bispecific, trispecific or multispecific.
44. The isolated protein of any one of claims 22 to 43, wherein the isolated protein is a heterodimer.
45. An isolated nucleic acid sequence comprising a nucleotide sequence encoding a polypeptide according to any one of claims 1 to 21 or a protein according to any one of claims 22 to 44.
46. An expression vector comprising the nucleic acid sequence according to claim 45.
47. An isolated cell expressing the polypeptide of any one of claims 1 to 21 or the protein of any one of claims 22 to 44.
48. An isolated cell comprising the nucleic acid sequence of claim 45 or the vector of claim 46.
49. A method for producing a polypeptide according to any one of claims 1 to 21 or a protein according to any one of claims 22 to 44, the method comprising culturing a cell according to claim 47 or 48.
50. The method of claim 49, further comprising isolating the polypeptide or the protein, A bispecific antibody or multispecific antibody comprises one or more target binding regions and an exposed C-terminus fused to a cap domain, wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37), and wherein the antibody exhibits reduced interaction with an anti-drug antibody relative to the interaction of the antibody with the anti-drug antibody in the absence of the cap domain.
51. The antibody of claim 50, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
52. The antibody of claim 50 or 51, wherein in an immunoassay, the antibody exhibits reduced interaction with an anti-drug antibody relative to the interaction of the antibody with the anti-drug antibody when the antibody lacks the His cap domain.
53. The antibody of any one of claims 50 to 52, wherein the one or more target binding regions comprise at least one antibody variable domain.
54. The antibody of claim 53, wherein the at least one antibody variable domain comprises a heavy chain variable domain or a light chain variable domain.
55. The antibody of any one of claims 50 to 54, wherein the His cap domain consists of a single histidine residue, two histidine residues, three histidine residues, four histidine residues (SEQ ID NO: 27) or five histidine residues (SEQ ID NO: 28).
56. The antibody of any one of claims 50 to 54, wherein the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of: (a) VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4) or VTVSSHHHHH (SEQ ID NO: 5); (b) VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9) or VEIKHHHHH (SEQ ID NO: 10); (c) VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14) or VEIKRHHHHH (SEQ ID NO: 15); (d) VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHHH (SEQ ID NO: 19) or VEIKRTHHHHH (SEQ ID NO: 20); or (e) the amino acid sequence of TKVTVL(His)n (SEQ ID NO:46), TKLTVL(His)n (SEQ ID NO:47), TQLIIL(His)n (SEQ ID NO:48), TELTVL(His)n (SEQ ID NO:49) or TQLTVL(His)n (SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.
57. The antibody of any one of claims 50 to 56, wherein the multispecific antibody comprises a trispecific antibody.
58. A nucleic acid sequence comprising a nucleotide sequence encoding the antibody according to any one of claims 50 or 57.
59. An expression vector comprising the nucleic acid sequence according to claim 58.
60. An isolated cell comprising the nucleic acid sequence of claim 58 or the vector of claim 59.
61. An isolated cell expressing the antibody of any one of claims 50 to 57.
62. A method for producing an antibody according to any one of claims 50 to 57, the method comprising culturing a cell according to claim 60 or 61.
63. The method of claim 62, further comprising isolating the antibody.
64. A method for reducing the interaction between an isolated polypeptide and a reference substance, wherein the isolated polypeptide comprises one or more target binding regions, and an exposed C-terminus, the method comprising fusing a cap domain at the end of the exposed C-terminus, wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37).
65. The method of claim 64, wherein the reference is a molecule present in biological matter.
66. The method of claim 65, wherein the biological substance comprises serum and / or plasma.
67. The method according to any one of claims 64 to 66, wherein the reference comprises anti-drug antibodies, optionally the anti-drug antibodies are pre-existing in the serum and / or plasma of the subject.
68. The method according to any one of claims 64 to 67, wherein the interaction with the reference is determined by an immunoassay.
69. The method of any one of claims 64 to 67, wherein the interaction with the reference substance is assessed in vitro or in vivo.
70. A method for reducing aggregation of an isolated polypeptide in a biological substance, wherein the isolated polypeptide comprises one or more target binding regions, and an exposed C-terminus, the method comprising fusing a cap domain at the end of the exposed C-terminus, wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37).
71. The method of claim 70, wherein the biological substance is human serum and / or plasma.
72. The method of claim 71, wherein incubating with the biological material comprises: (a) incubating at about 37°C for about 2 days to about 5 days, about 2 days to about 7 days, or about 5 days to about 14 days; (b) incubating at about 40°C for about 2 days to about 5 days, about 2 days to about 7 days, or about 7 days to about 14 days; (c) incubating at about 4°C for about 2 days to about 5 days, about 2 days to about 7 days, or about 7 days to about 14 days; or (d) incubating at about 25°C for about 2 days to about 5 days, about 2 days to about 7 days, or about 7 days to about 14 days.
73. The method of any one of claims 70 to 72, wherein the biological substance comprises anti-drug antibodies, optionally the anti-drug antibodies are pre-existing in the serum and / or plasma of the subject.
74. The method of any one of claims 70 to 73, wherein the interaction with the biological substance is assessed by size exclusion chromatography.
75. A method for reducing self-aggregation of an isolated polypeptide, wherein the isolated polypeptide comprises one or more target binding regions, and an exposed C-terminus, the method comprising fusing a cap domain at the end of the exposed C-terminus, wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37).
76. The method of claim 75, wherein self-aggregation is reduced in a high concentration liquid formulation (HCLF).
77. The method of claim 76, wherein the HCLF concentration comprises about 50 mg / mL to about 150 mg / mL of the isolated polypeptide.
78. The method of any one of claims 75 to 77, wherein self-aggregation is reduced under heat stress.
79. The method of claim 78, wherein heat stress comprises incubation at 40°C for about two weeks.
80. The method of any one of claims 75 to 79, wherein the self-aggregation is assessed by size exclusion chromatography.
81. The method of any one of claims 64 to 80, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
82. The method of any one of claims 64 to 81, wherein the one or more target binding regions comprise an antibody variable domain or an antigen binding fragment thereof.
83. The method of any one of claims 64 to 81, wherein the one or more target binding regions comprise a light chain antibody variable domain or an antigen binding fragment thereof and / or a heavy antibody variable domain or an antigen binding fragment thereof.
84. The method of any one of claims 64 to 82, wherein the His cap domain consists of a single histidine residue, two histidine residues, three histidine residues, four histidine residues (SEQ ID NO: 27) or five histidine residues (SEQ ID NO: 28).
85. The method of any one of claims 64 to 82, wherein the exposed C-terminus fused to the His cap domain consists of an amino acid sequence selected from the group consisting of: (a) VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4) and VTVSSHHHHH (SEQ ID NO: 5); (b) VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9) and VEIKHHHHH (SEQ ID NO: 10); (c) VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14) and VEIKRHHHHH (SEQ ID NO: 15); (d) VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHHH (SEQ ID NO: 19) and VEIKRTHHHHH (SEQ ID NO: 20); or (e) the amino acid sequence of TKVTVL(His)n (SEQ ID NO:46), TKLTVL(His)n (SEQ ID NO:47), TQLIIL(His)n (SEQ ID NO:48), TELTVL(His)n (SEQ ID NO:49) or TQLTVL(His)n (SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.
86. A method for reducing the interaction between an isolated protein and a reference substance, wherein the isolated protein comprises: (a) a first polypeptide comprising a target binding region and an exposed C-terminus; and (b) a second polypeptide, the second polypeptide comprising a target binding region, The method comprises fusing a cap domain at the end of the exposed C-terminus of the first polypeptide, wherein the cap domain is a His cap domain, or consists of an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37).
87. The method of claim 86, wherein the target binding regions of the first polypeptide and the second polypeptide are capable of binding to different targets.
88. The method of claim 86 or 87, wherein the exposed C-terminus of the first polypeptide comprises an anti-drug antibody epitope.
89. The method of any one of claims 86 to 88, wherein the target binding region of the second polypeptide comprises an antibody variable domain or an antigen binding fragment thereof.
90. The method of any one of claims 86 to 88, wherein the target binding region of the second polypeptide comprises a light chain antibody variable domain or an antigen binding fragment thereof and / or a heavy chain antibody variable domain or an antigen binding fragment thereof.
91. The method of any one of claims 86 to 90, wherein the second polypeptide comprises an exposed C-terminus, and the method further comprises fusing a cap domain to the end of the exposed C-terminus of the second polypeptide, wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36), TVAPTESS (SEQ ID NO: 37), HHHHHH (SEQ ID NO: 26), or AS.
92. The method of claim 91, wherein the exposed C-terminus of the second polypeptide comprises an anti-drug antibody epitope.
93. The method of claim 91 or 92, wherein the His cap domain of the second polypeptide consists of a single histidine residue, two histidine residues, three histidine residues, four histidine residues (SEQ ID NO: 27) or five histidine residues (SEQ ID NO: 28).
94. The method of claim 91 or 92, wherein the exposed C-terminus fused to the His cap domain of the second polypeptide consists of an amino acid sequence selected from the group consisting of: (a) VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4) and VTVSSHHHHH (SEQ ID NO: 5); (b) VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9) and VEIKHHHHH (SEQ ID NO: 10); (c) VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14) and VEIKRHHHHH (SEQ ID NO: 15); (d) VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHHH (SEQ ID NO: 19) and VEIKRTHHHHH (SEQ ID NO: 20); or (e) the amino acid sequence of TKVTVL(His)n (SEQ ID NO:46), TKLTVL(His)n (SEQ ID NO:47), TQLIIL(His)n (SEQ ID NO:48), TELTVL(His)n (SEQ ID NO:49) or TQLTVL(His)n (SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.
95. The method of any one of claims 86 to 94, wherein the target binding region of the first polypeptide comprises an antibody variable domain or an antigen binding fragment thereof.
96. The method of any one of claims 86 to 94, wherein the target binding region of the first polypeptide comprises a light chain antibody variable domain or an antigen binding fragment thereof and / or a heavy chain antibody variable domain or an antigen binding fragment thereof.
97. The method of any one of claims 86 to 96, wherein the His cap domain of the first polypeptide consists of a single histidine residue, two histidine residues, three histidine residues, four histidine residues (SEQ ID NO: 27) or five histidine residues (SEQ ID NO: 28).
98. The method of any one of claims 86 to 96, wherein the exposed C-terminus fused to the His cap domain of the first polypeptide consists of an amino acid sequence selected from the group consisting of: (a) VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4) and VTVSSHHHHH (SEQ ID NO: 5); (b) VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9) and VEIKHHHHH (SEQ ID NO: 10); (c) VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14) and VEIKRHHHHH (SEQ ID NO: 15); (d) VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHHH (SEQ ID NO: 19) and VEIKRTHHHHH (SEQ ID NO: 20); or (e) the amino acid sequence of TKVTVL(His)n (SEQ ID NO:46), TKLTVL(His)n (SEQ ID NO:47), TQLIIL(His)n (SEQ ID NO:48), TELTVL(His)n (SEQ ID NO:49) or TQLTVL(His)n (SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.
99. The method of any one of claims 86 to 98, wherein the isolated protein further comprises a third polypeptide comprising a target binding region.
100. The method of claim 99, wherein the third polypeptide is capable of binding to a target different from the first polypeptide, the second polypeptide, or both.
101. The method of claim 99 or 100, wherein the target binding region of the third polypeptide comprises an antibody variable domain or an antigen binding fragment thereof.
102. The method of claim 99 or 100, wherein the target binding region of the third polypeptide comprises a light chain antibody variable domain or an antigen binding fragment thereof and / or a heavy chain antibody variable domain or an antigen binding fragment thereof.
103. The method of any one of claims 99 to 102, wherein the third polypeptide comprises an exposed C-terminus, and the method further comprises fusing a cap domain to the end of the exposed C-terminus of the third polypeptide, wherein the cap domain is a His cap domain, or consists of an amino acid sequence of SLSLSPGK (SEQ ID NO: 36), TVAPTESS (SEQ ID NO: 37), HHHHHH (SEQ ID NO: 26), or AS.
104. The method of claim 103, wherein the exposed C-terminus of the third polypeptide comprises an anti-drug antibody epitope.
105. The method of claim 103 or 104, wherein the His cap domain of the third polypeptide consists of a single histidine residue, two histidine residues, three histidine residues, four histidine residues (SEQ ID NO: 27) or five histidine residues (SEQ ID NO: 28).
106. The method of claim 103 or 104, wherein the exposed C-terminus of the third polypeptide fused to the His cap domain consists of an amino acid sequence selected from the group consisting of: (a) VTVSSH (SEQ ID NO: 1), VTVSSHH (SEQ ID NO: 2), VTVSSHHH (SEQ ID NO: 3), VTVSSHHHH (SEQ ID NO: 4) and VTVSSHHHHH (SEQ ID NO: 5); (b) VEIKH (SEQ ID NO: 6), VEIKHH (SEQ ID NO: 7), VEIKHHH (SEQ ID NO: 8), VEIKHHHH (SEQ ID NO: 9) and VEIKHHHHH (SEQ ID NO: 10); (c) VEIKRH (SEQ ID NO: 11), VEIKRHH (SEQ ID NO: 12), VEIKRHHH (SEQ ID NO: 13), VEIKRHHHH (SEQ ID NO: 14) and VEIKRHHHHH (SEQ ID NO: 15); (d) VEIKRTH (SEQ ID NO: 16), VEIKRTHH (SEQ ID NO: 17), VEIKRTHHH (SEQ ID NO: 18), VEIKRTHHHHH (SEQ ID NO: 19) and VEIKRTHHHHH (SEQ ID NO: 20); or (e) the amino acid sequence of TKVTVL(His)n (SEQ ID NO:46), TKLTVL(His)n (SEQ ID NO:47), TQLIIL(His)n (SEQ ID NO:48), TELTVL(His)n (SEQ ID NO:49) or TQLTVL(His)n (SEQ ID NO:50), wherein n is 1, 2, 3, 4 or 5.
107. The method of any one of claims 86 to 106, wherein the isolated protein is bispecific, trispecific or multispecific.
108. The method of any one of claims 86 to 107, wherein the isolated protein is a heterodimer.
109. A capping component for reducing the interaction between an isolated polypeptide and a reference substance, wherein the isolated polypeptide comprises one or more target binding regions, and an exposed C-terminus.
110. The capping component of claim 109, wherein the one or more target binding regions comprise an antibody variable domain or an antigen binding fragment thereof.
111. The capping member of claim 109 or 110, wherein the reference is a molecule present in biological matter.
112. The capping member of claim 111, wherein the biological substance comprises serum.
113. The capping member of any one of claims 109 to 112, wherein the reference comprises an anti-drug antibody.
114. The capping component of any one of claims 109 to 113, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
115. The capping member of any one of claims 109 to 114, wherein the exposed C-terminus consists of an amino acid sequence selected from the group consisting of: VTVSS(SEQ ID NO:21), VEIK(SEQ ID NO:22), VEIKR(SEQ ID NO:23), VEIKRT(SEQ ID NO:24), TKVTVL(SEQ ID NO:38), TKLTVL(SEQ ID NO:39), TQLIIL(SEQ ID NO:40), TELTVL(SEQ ID NO:41) and TQLTVL (SEQ ID NO:42).
116. A capping component for reducing the interaction between an isolated protein and a reference, wherein the isolated protein comprises: (a) a first polypeptide comprising a target binding region and an exposed C-terminus; and (b) a second polypeptide comprising a target binding region.
117. The capping component of claim 116, wherein the second polypeptide comprises an exposed C-terminus.
118. The capping component of claim 116 or 117, wherein the target binding regions of the first polypeptide and the second polypeptide are capable of binding to different targets.
119. The capping member of any one of claims 116 to 118, wherein the isolated protein further comprises a third polypeptide comprising a target binding region.
120. The capping component of claim 119, wherein the third polypeptide comprises an exposed C-terminus.
121. The capping component of claim 119 or 120, wherein the third polypeptide is capable of binding to a target different from the first polypeptide, the second polypeptide, or both.
122. The capping member of any one of claims 116 to 121, wherein the isolated protein is a heterodimer.
123. The capping member of any one of claims 116 to 122, wherein the isolated protein is bispecific, trispecific or multispecific.
124. The capping component of any one of claims 116 to 123, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
125. The capping member of any one of claims 116 to 123, wherein the exposed C-terminus consists of an amino acid sequence selected from the group consisting of: VTVSS(SEQ ID NO:21), VEIK(SEQ ID NO:22), VEIKR(SEQ ID NO:23), VEIKRT(SEQ ID NO:24), TKVTVL(SEQ ID NO:38), TKLTVL(SEQ ID NO:39), TQLIIL(SEQ ID NO:40), TELTVL(SEQ ID NO:41) and TQLTVL (SEQ ID NO:42).
126. A capping component for reducing the interaction between a bispecific antibody or a multispecific antibody and a reference, wherein the bispecific antibody or the multispecific antibody comprises one or more target binding regions, and an exposed C-terminus.
127. The capping component of claim 126, wherein the one or more target binding regions comprise at least one antibody variable domain.
128. The capping component of claim 127, wherein the at least one antibody variable domain comprises a heavy chain variable domain or a light chain variable domain.
129. The capping component of any one of claims 126 to 128, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
130. The capping member of any one of claims 126 to 129, wherein the multispecific antibody comprises a trispecific antibody.
131. The capping member of any one of claims 109 to 130, wherein the capping member is a histidine capping member.
132. An isolated polypeptide and a capping component for reducing the interaction between the isolated polypeptide and a reference substance, wherein the isolated polypeptide comprises one or more target binding regions, and an exposed C-terminus.
133. The isolated polypeptide of claim 132, wherein the one or more target binding regions comprise an antibody variable domain or an antigen binding fragment thereof.
134. The isolated polypeptide of claim 132 or 133, wherein the reference is a molecule present in a biological substance.
135. The isolated polypeptide of claim 134, wherein the biological substance comprises serum and / or plasma.
136. The isolated polypeptide of any one of claims 132 to 135, wherein the reference comprises anti-drug antibodies, optionally pre-existing in the serum and / or plasma of a subject.
137. The isolated polypeptide of any one of claims 132 to 136, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
138. The isolated polypeptide of any one of claims 132 to 136, wherein the exposed C-terminus consists of an amino acid sequence selected from the group consisting of: VTVSS(SEQ ID NO:21), VEIK(SEQ ID NO:22), VEIKR(SEQ ID NO:23), VEIKRT(SEQ ID NO:24), TKVTVL(SEQ ID NO:38), TKLTVL(SEQ ID NO:39), TQLIIL(SEQ ID NO:40), TELTVL(SEQ ID NO:41) and TQLTVL (SEQ ID NO:42).
139. An isolated protein and a capping member for reducing the interaction between the isolated protein and a reference substance, wherein the isolated protein comprises: (a) a first polypeptide comprising a target binding region and an exposed C-terminus; and (b) a second polypeptide comprising a target binding region.
140. The isolated protein of claim 139, wherein the second polypeptide comprises an exposed C-terminus.
141. The isolated protein of claim 139 or 140, wherein the target binding regions of the first polypeptide and the second polypeptide are capable of binding to different targets.
142. The isolated protein of any one of claims 139 to 141, wherein the isolated protein further comprises a third polypeptide comprising a target binding region.
143. The isolated protein of claim 142, wherein the third polypeptide comprises an exposed C-terminus.
144. The isolated protein of claim 142 or 143, wherein the third polypeptide is capable of binding to a target different from the first polypeptide, the second polypeptide, or both.
145. The isolated protein of any one of claims 139 to 144, wherein the isolated protein is a heterodimer.
146. The isolated protein of any one of claims 139 to 145, wherein the isolated protein is bispecific, trispecific or multispecific.
147. The isolated protein of any one of claims 139 to 146, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
148. The isolated polypeptide or isolated protein of any one of claims 132 to 147, wherein the capping component is a histidine capping component.
149. A bispecific antibody or a multispecific antibody and a capping component for reducing the interaction between the bispecific antibody or the multispecific antibody and a reference, wherein the bispecific antibody or the multispecific antibody comprises one or more target binding regions, and an exposed C-terminus.
150. The antibody of claim 149, wherein the one or more target binding regions comprise at least one antibody variable domain.
151. The antibody of claim 150, wherein the at least one antibody variable domain comprises a heavy chain variable domain or a light chain variable domain.
152. The antibody of any one of claims 149 to 151, wherein the bispecific antibody or the multispecific antibody is a heterodimer.
153. The antibody of any one of claims 149 to 152, wherein the multispecific antibody comprises a trispecific antibody.
154. The antibody of any one of claims 149 to 153, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
155. The antibody of any one of claims 149 to 154, wherein the capping member is a histidine capping member.
156. An isolated protein for use in a diagnostic assay, the isolated protein comprising a target binding region and an exposed C-terminus fused to a cap domain, wherein the cap domain consists of a His cap domain, or an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37).
157. The protein for use according to claim 156, wherein the protein is an antibody.
158. The protein for use according to claim 157, wherein the antibody binds to: glioma-associated antigen, carcinoembryonic antigen (CEA), beta-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostein, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin.
159. The protein for use according to claim 157, wherein the antibody binds to an antigen of a pathogen.
160. The protein for use according to claim 159, wherein the pathogen is a virus, a bacterium, a fungus or a parasite.
161. A protein for use according to any one of claims 156 to 160, wherein the protein is used in a diagnostic assay to detect the presence of a molecule in a biological substance.
162. The protein for use according to claim 161, wherein the molecule is an antigen.
163. The protein for use according to claim 161 or 162, wherein the biological substance is serum and / or plasma.
164. The protein for use according to any one of claims 156 to 163, wherein the diagnostic assay is performed in vitro or in vivo.
165. The protein for use according to any one of claims 156 to 164, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
166. The protein for use according to any one of claims 156 to 164, wherein the exposed C-terminus consists of an amino acid sequence selected from the group consisting of: VTVSS(SEQ ID NO:21), VEIK(SEQ ID NO:22), VEIKR(SEQ ID NO:23), VEIKRT(SEQ ID NO:24), TKVTVL(SEQ ID NO:38), TKLTVL(SEQ ID NO:39), TQLIIL(SEQ ID NO:40), TELTVL(SEQ ID NO:41) and TQLTVL (SEQ ID NO:42).
167. An isolated therapeutic protein for use in therapy, the isolated therapeutic protein comprising a target binding region and an exposed C-terminus fused to a cap domain, wherein the cap domain consists of a His cap domain, or an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37).
168. The protein for use according to claim 167, wherein the protein is a cytokine or an antibody.
169. The protein for use according to claim 168, wherein the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9 or IL-17.
170. The protein for use according to claim 168, wherein the antibody binds to: glioma-associated antigen, carcinoembryonic antigen (CEA), beta-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2(AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostein, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin.
171. The protein for use according to claim 168, wherein the antibody binds to an antigen of a pathogen.
172. The protein for use according to claim 171, wherein the pathogen is a virus, bacteria, fungus or parasite.
173. The protein for use according to any one of claims 167 to 172, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
174. The protein for use according to any one of claims 167 to 172, wherein the exposed C-terminus consists of an amino acid sequence selected from the group consisting of: VTVSS(SEQ ID NO:21), VEIK(SEQ ID NO:22), VEIKR(SEQ ID NO:23), VEIKRT(SEQ ID NO:24), TKVTVL(SEQ ID NO:38), TKLTVL(SEQ ID NO:39), TQLIIL(SEQ ID NO:40), TELTVL(SEQ ID NO:41) and TQLTVL (SEQ ID NO:42).
175. An isolated protein comprising a target binding region and an exposed C-terminus fused to a cap domain, wherein the exposed C-terminus consists of the amino acid sequence VTVSS (SEQ ID NO:21), VEIK (SEQ ID NO:22), VEIKR (SEQ ID NO:23), VEIKRT (SEQ ID NO:24), TKVTVL (SEQ ID NO:38), TKLTVL (SEQ ID NO:39), TQLIIL (SEQ ID NO:40), TELTVL (SEQ ID NO:41) or TQLTVL (SEQ ID NO:42), and wherein the cap domain consists of the amino acid sequence of a His cap domain or SLSLSPGK (SEQ ID NO:36) or TVAPTESS (SEQ ID NO:37).
176. The protein of claim 175, wherein the protein is an antibody.
177. The protein of claim 176, wherein the antibody binds to: glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B-cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2(AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostein, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin.
178. The protein of claim 176, wherein the antibody binds to an antigen of a pathogen.
179. The protein for use according to claim 178, wherein the pathogen is a virus, bacteria, fungus or parasite.
180. A therapeutic bispecific antibody or multispecific antibody for use in therapy, comprising two or more target binding regions and an exposed C-terminus fused to a cap domain, wherein the cap domain is a His cap domain, or an amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37).
181. The bispecific antibody or multispecific antibody for use according to claim 180, wherein the two or more target binding regions bind to two or more antigens.
182. The bispecific antibody or multispecific antibody for use according to claim 181, wherein at least one antigen is selected from the group consisting of: glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B-cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2(AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostein, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor and mesothelin.
183. The bispecific antibody or multispecific antibody of claim 180, wherein the antibody binds to an antigen of a pathogen.
184. The protein for use according to claim 183, wherein the pathogen is a virus, bacteria, fungus or parasite.
185. The bispecific antibody or multispecific antibody of any one of claims 180 to 184, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
186. The bispecific antibody or multispecific antibody of any one of claims 180 to 185, wherein the exposed C-terminus consists of an amino acid sequence selected from the group consisting of: VTVSS(SEQ ID NO:21), VEIK(SEQ ID NO:22), VEIKR(SEQ ID NO:23), VEIKRT(SEQ ID NO:24), TKVTVL(SEQ ID NO:38), TKLTVL(SEQ ID NO:39), TQLIIL(SEQ ID NO:40), TELTVL(SEQ ID NO:41) or TQLTVL (SEQ ID NO:42).
187. A pharmaceutical composition for use in therapy, comprising a protein according to any one of claims 175 to 179 and a pharmaceutically acceptable excipient.
188. A pharmaceutical composition for use in a diagnostic assay, comprising a protein according to any one of claims 175 to 179 and a pharmaceutically acceptable excipient.
189. Use of a cap domain for reducing the interaction between an anti-drug antibody and a protein, wherein the protein comprises one or more target binding regions, and an exposed C-terminus, and wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37).
190. Use of a cap domain for reducing aggregation in biological substances, wherein the protein comprises one or more target binding regions, and an exposed C-terminus, and wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37).
191. Use of a cap domain for reducing self-aggregation, wherein the protein comprises one or more target binding regions, and an exposed C-terminus, and wherein the cap domain is a His cap domain, or consists of the amino acid sequence of SLSLSPGK (SEQ ID NO: 36) or TVAPTESS (SEQ ID NO: 37).
192. The use according to claim 190, wherein the biological substance comprises serum and / or plasma.
193. The use according to any one of claims 189 to 191, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
194. The use according to any one of claims 189 to 191, wherein the cap domain is a His cap domain consisting of one, two, three, four or five histidines.
195. An isolated protein comprising a target binding region and an exposed C-terminus fused to a cap domain, wherein the cap domain consists of a His cap domain or an amino acid sequence of HHHHHH (SEQ ID NO: 26), SLSLSPGK (SEQ ID NO: 36) or AS, TVAPTESS (SEQ ID NO: 37).
196. The isolated protein of claim 195, wherein the isolated protein exhibits reduced interaction with anti-drug antibodies in biological substances.
197. The isolated protein of claim 196, wherein the biological substance comprises serum and / or plasma.
198. An isolated protein according to any one of claims 195 to 197, wherein the exposed C-terminus comprises an anti-drug antibody epitope.
199. The isolated protein of any one of claims 195 to 198, wherein the exposed C-terminus consists of an amino acid sequence selected from the group consisting of: VTVSS(SEQ ID NO:21), VEIK(SEQ ID NO:22), VEIKR(SEQ ID NO:23), VEIKRT(SEQ ID NO:24), TKVTVL(SEQ ID NO:38), TKLTVL(SEQ ID NO:39), TQLIIL(SEQ ID NO:40), TELTVL(SEQ ID NO:41) or TQLTVL (SEQ ID NO:42).
200. The isolated protein of any one of claims 195 to 199 for use in a therapeutic or diagnostic assay.
